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Roquin is an important factor in the prevention of autoimmune diseases.  It limits the 
expression of the inducible T cell co-stimulator (ICOS) in T cells.  This function is essential 
for the repression of self-antigen-triggered immune responses.   
This thesis reveals a new mechanism by which Roquin exerts posttranscriptional gene 
silencing of ICOS.  The findings uncover that Roquin has specialized in efficient translational 
repression of ICOS, unlike its paralog MNAB.  Two parts within the Roquin protein provide 
essential functions for this repression.  First, the carboxy-terminus localizes Roquin to P 
bodies, which are cytoplasmic loci enriched in translationally inactive mRNAs and proteins 
that are involved in translational inhibition.  Second, the amino-terminus of Roquin can bind 
ICOS mRNA, for which a recently defined ROQ domain is critical.  The amino-terminus can 
be functionally replaced by conserved sequences from Roquin’s paralog MNAB, indicating a 
possible role of MNAB as a translational repressor. 
A recent study suggested that microRNAs are involved in Roquin-mediated ICOS repression.  
These small non-coding RNAs can inhibit translation of mRNAs through the binding of 
partially complementary sites in the 3'UTR of the target gene.  However, the biochemical 
analysis presented here disproves this concept and reveals an alternative pathway for Roquin-
mediated ICOS repression.   
The contribution of microRNAs for Roquin-mediated ICOS silencing was analyzed in two 
independent approaches: first in cells deficient in Dicer, which are incapable of microRNA 
biogenesis, and second in cells deficient in Argonaute 1-4 proteins, which are impaired in 
microRNA induced silencing complex (miRISC) formation.  The data show that Roquin can 
silence ICOS even in the absence of microRNAs and miRISC formation, thereby excluding 
their requirement.   
Instead, Roquin activity is inhibited by experimentally induced miRISC formation, but 
requires intact function of the P body components GW182, Lsm1 and Rck.  Taken together, 
the data presented place Roquin-mediated translational repression parallel to the miRNA 
pathway.
1 Abstract 
  
 
 
Roquin ist ein wichtiger Faktor in der Prävention von Autoimmunerkrankungen.  Roquin 
reprimiert die Expression des induzierbaren co-stimulatorischen Rezeptors (ICOS) auf          
T-Zellen und gewährleistet somit, dass keine Immunantwort gegen Selbst-Antigene 
stattfinden kann. 
Diese Doktorarbeit präsentiert den Mechanismus, durch welchen Roquin ICOS 
posttranscriptional reguliert.  Die Ergebnisse zeigen, dass Roquin, im Gegensatz zu seinem 
Paralog MNAB, effectiv die Translation von ICOS reprimieren kann.  Die carboxy-, sowie 
die aminoterminale Regionen des Roquin-Proteins besitzen die dafür notwendigen 
Funktionen.  Die carboxyterminale Region lokalisiert Roquin zu sogenannten P bodies, in 
denen translational reprimierte mRNAs und Proteine, die an translationaler Repression 
beteiligt sind, ebenfalls lokalisieren.  Die aminoterminale Region von Roquin, insbesondere 
die neu definierte ROQ-Domäne, kann an ICOS-mRNA binden und ermöglicht dadurch eine 
Repression von ICOS.  Die aminoterminale Region von Roquin kann durch die stark 
konservierte aminoterminale Sequenz von MNAB funktionell ersetzt werden. Dies weist 
darauf hin, dass MNAB ebenso ein regulatorisches Protein sein könnte, jedoch von zur Zeit 
nicht identifizierten Ziel-Genen.  
In einer vorausgegangenen Veröffentlichung wurde vorgeschlagen, dass Roquin mit miRNAs 
kooperiert, um ICOS zu reprimieren.  MiRNAs sind kleine, nicht-kodierende RNAs, die die 
Translation von kodierenden mRNAs inhibieren können, indem sie an 3'UTR der Ziel-Gene 
binden.  Diese Arbeit widerlegt das aktuelle Konzept und zeigt einen neuen alternativen 
molekularen Mechanismus für Roquin auf.  Die mögliche Beteiligung von miRNAs für 
Roquin-vermittelte ICOS Repression wurde in zwei unabhängigen Ansätzen überprüft: zum 
Einem in Dicer-defizienten Zellen, in denen keine miRNA-Biogenese stattfinden kann, und 
zum Anderen in Argonaute 1-4-defizienten Zellen, in denen keine "miRNA induced silencing 
complex" (miRISC)-Formation stattfinden kann.  Die Daten zeigen eindeutig, dass Roquin-
vermittelte ICOS-Repression, auch in der Abwesenheit von miRNAs oder miRISC-
Formation, unverändert stattfinden kann. Damit wird eine Beteiligung von miRNAs für 
Roquin-Aktivität ausgeschlossen.   
Stattdessen wurde entdeckt, dass Roquin-Aktivität sogar durch experimentell induzierte 
miRISC-Formation inhibiert wurde und dass Roquin die intakte Funktion der P body-
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Faktoren GW182, Lsm1 und Rck benötigt.  Zusammenfassend zeigen die hier präsentierten 
Daten, dass die Roquin-vermittelte Repression parallel zur miRNA-vermittelten Repression 
verläuft.   
  
 
The following format was used when writing genes, mRNAs or proteins: 
 
Gene Mrna Protein 
 
Table 3-1 Abbreviations: 
 
% percent 
°C degree Celsius 
5'CAP modified nucleotide on the 5'end of the mRNA 
aa amino acid 
Ago Argonaute (protein) 
ARE AU-rich sequences 
BCR B cell receptor 
BSA bovine serum albumin 
cDNA complementary DNA 
CDS coding sequence 
CpG 
DNA regions with cysteine nucleotides occur next to guanine nucleotides in a 
stretch of bases 
DNA deoxyribonucleic acid 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmatic reticulum 
ES cell Embryonic stem cell 
FL full length 
ICOS inducible T cell co-stimulatory molecule 
IRE iron-response element 
IRES internal ribosome entry site 
kDa kilo Dalton 
LB media Luria-Bertani media 
min minute 
miR microRNA 
miRNA microRNA 
MNAB Membrane nucleic acid binding protein 
MOI multiplicity of infection 
mRNA messenger ribonucleic acid 
NMD nonsense mediated mRNA decay 
NMD number 
ORF open reading frame 
P body processing bodies 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
pH potentio hydrogeni 
3 Abbreviations and scientific notation
Abbreviations and scientific notation   7 
poly(A) 
tail polyadenylated 3'end of mRNA 
RING really interesting new gene 
RISC RNA-induced silencing complex 
RNAse ribonuclease 
rpm revolutions per minute 
san sanroque gene that encodes for Roquin 
SDS sodium dodecyl sulfate 
sh RNA small hairpin RNA 
SLE systematic lupus erythematosus 
TCR T-cell receptor 
TFH follicular helper T cells 
TIA-1 T cell internal antigen-1 
TTP Tristetraprolin 
UTR untranslated region  
v/v volume per volume 
w/v weight per volume 
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5.1 Motivation of the research work  
The primary aim was to investigate the mechanism of posttranscriptional regulation using 
Roquin and its repression of ICOS as a molecular model system.  Although mRNA regulation 
is an important topic in scientific research, only some mechanisms have been discovered so 
far (section 5.3).  It was recently proposed that microRNAs, a novel class of translational 
repressors, are required for Roquin's activity [1], but the molecular mechanism remained 
unclear.  Understanding how Roquin exerts its repressive activity on ICOS could elucidate a 
new concept of mRNA regulation.   
Roquin plays a critical role in the prevention of autoimmune diseases and was only recently 
discovered (section 5.2).  Autoimmune diseases arise in most cases due to complex genetic 
predispositions and/or environmental triggers.  There are only few reports showing that 
mutations in individual genes can disable central control mechanisms of the immune system 
against self-reactivity leading to autoimmunity (section 5.2).  However, mutations in the 
Roquin as well as in the ICOS gene have been reported to cause autoimmune diseases in 
mouse and man [2-6].  Roquin limits ICOS expression in T cells [1].  Consequently, the 
discovery of the mechanism by which Roquin represses ICOS has potential for the 
development of therapeutics against autoimmune diseases, in which deregulation of ICOS is 
causal. 
5 Introduction 
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5.2 Autoimmunity  
Autoimmunity is defined as an immune response of an organism against its own cells and 
tissues.  The immune system fails to discriminate the body’s own from foreign constituents.  
In autoimmune diseases, self-antigens, in addition to foreign antigens, trigger an immune 
response.  Autoimmunity can lead to organ-specific or systemic symptoms.  In the case of an 
organ-specific autoimmune disease, only one or few organs are targeted, e.g. the islets of 
Langerhans in the pancreas in the case of type 1 diabetes mellitus.  In the case of systemic 
autoimmune disease, e.g. systemic lupus erythematosus (SLE), multiple organs are targeted 
[7].   
Every individual in the animal kingdom is constantly exposed to an enormous diversity of 
pathogens.  Components of the innate immune system can recognize common evolutionary 
conserved features of pathogens, e.g. unmethylated CpG DNA, and trigger the innate 
response to effectively diminish the invading pathogen [7].  Owing to short generation 
intervals, microorganisms can evolve more rapidly than the host they infect and therefore may 
escape this defense system.  Therefore, a second line of defense, the so-called "adaptive 
immune system", has evolved in vertebrates to overcome main constraints of the innate 
immune system [7].  The adaptive immune response contains an enormous repertoire of 
receptors, which allows recognition of an almost infinite diversity of antigens [7].  
Lymphocytes, also referred to as T and B cells, ensure a specific immune response after 
exposure to a pathogen, resulting in lifelong immunity [7].  However, the adaptive immune 
system is not only beneficial for the host.  The huge diversity of receptors also bears a high 
risk in recognizing self-antigens by mistake, leading to autoimmune diseases.  B and T cells 
can potentially recognize any antigen through surface-expressed B cell receptors (BCRs) or T 
cell receptors (TCRs), respectively [7].  The diversity is provided by two processes of somatic 
recombination and mutation of antigen receptor genes.  First, the recombination of the 
variable (V), diversity (D) and joining (J) genes assembles unique BCR and TCR genes from 
three different gene segments.  Second, somatic hypermutation substitutes single nucleotides 
of BCR genes in the late phase of an immune response.  Millions of different receptors can be 
created by these two processes [7].  It is therefore rather surprising that only 3-8 % of the 
population develop an autoimmune disease during their life [8], especially since a significant 
fraction of T and B cell receptors can recognize self-antigen [9].  However, the immune 
system has not only developed ways to fight pathogens.  Simultaneously, numerous and 
efficient mechanisms co-evolved to prevent harmful responses against self.   
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During immune reactions, the body produces effector T cells and B cells, which secrete 
antibodies that neutralize and diminish intruding pathogens.  T or B cells develop in the 
central lymphoid tissues, the thymus or the bone marrow, respectively.  Here, somatic gene 
recombination takes place allowing the production of surface bound TCRs and BCRs [7].  
Mature T and B cells enter the periphery where they can be activated by receiving two signals 
from so-called antigen-presenting cells (APCs).  Dendritic cells are the most abundant APCs 
and become activated upon receptor-independent uptake (macropinocytosis) of pathogens or 
infected tissue debris [7].  APCs degrade pathogen-derived proteins, subsequent to 
macropinocytosis, and present the generated peptides as antigens on the surface of major 
histocompatibility complexes (MHC) (signal 1) to the TCR of the T cell [7].  Signal 1 can 
only effectively activate T cells if provided along with co-stimulatory signals, for example 
through the co-receptor CD28 (signal 2) [7].  CD28 signaling is enhanced after upregulation 
of the CD28 ligand, also called B7, which occurs during pathogen-induced inflammation [10].  
Thereby, effective T cell activation and T cell-induced immune responses are in most cases 
restricted to foreign antigen [10].  There are two main T cell-mediated immune responses.  
First, CD8 killer T cells themselves act by inducing apoptosis in infected cells of the body.  
Second, CD4 helper T cells upregulate co-stimulatory molecules and secrete cytokines to 
activate other cells of the immune system, such as macrophages, granulocytes and B cells.  B 
cells can also be activated independently of T cell help by some microbial antigens, resulting 
in low-affinity antibodies produced in a rapid immune response [11].  However, for the 
generation of high-affinity antibodies, B cells differentiate in peripheral lymphoid tissues and 
undergo somatic hypermutation of their (V) gene region [7].  To avoid loss of affinity or gain 
of self-reactivity in this process, B cells require T cell help, executed in the so-called germinal 
center reaction [11].  This help is provided by follicular T helper (TFH) cells, to which the B 
cells present the recognized antigen.  TFH cells highly express the inducible co-receptor ICOS 
as well as the co-stimulatory molecule CD40L and secrete interleukin-21, an important 
cytokine for the stimulation of the germinal center B cells.  A positive interaction results in 
the selection of high-affinity memory B cells and long-lived plasma cells, which produce 
high-affinity antibodies [11]. 
During development, maturation and activation of lymphocytes, several mechanisms act 
together to prevent an immune response against self-antigens [9].  First, the lymphocytes that 
rearrange receptors with self-reactivity are triggered to undergo apoptosis, a process termed 
"clonal deletion" [7].  Second, B cells employ receptor editing to diminish self-reactivity of 
the BCR [12].  Third, self-reactive T and B cells that have escaped early control mechanisms 
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can be extrinsically suppressed [9], either by limiting essential factors for activation and 
survival (e.g. co-stimuli, essential growth factors or pro-inflammatory mediators) or by active 
suppression (e.g. through regulatory T cells or the secretion of anti-inflammatory cytokines) 
[9, 13-15].  Finally, a mechanism termed ‘anergy’ can cell-intrinsically reduce the ability of T 
and B cells to be activated through self-antigens [16-18].  A variety of proteins involved in 
such control mechanisms ensure the discrimination between self and foreign antigens, and the 
expression levels of these proteins are tightly controlled.  For example, aberrant high 
expression of the inducible T cell co-stimulatory molecule (ICOS) was correlated with T cell 
activation and germinal center responses triggered by self-antigen [19].  In agreement with 
this, the newly discovered protein Roquin has been reported to play a crucial role in the 
prevention of autoimmune diseases by limiting ICOS expression in T cells [1].  Roquin was 
discovered in an ethylnitrosourea (ENU) screen in mice testing for the generation of auto-
antibodies.  ENU generates single base pair substitutions at an estimated rate of ~2 per 
megabase in the germline [2]. 
The so-called sanroque mouse carries one point-mutation in the Rc3h1 gene, which causes an 
amino acid exchange in the Roquin protein at position 199 from methionine to arginine 
(M199R) [2].  The homozygous san/san mouse develops a severe autoimmune disease that 
resembles SLE in humans [2].  Patients with SLE suffer from periods of illness, including 
fever, malaise, joint pain, fatigue, myalgias and loss of cognitive abilities.  SLE can be fatal, 
however due to improved diagnostic tests and subsequent treatment with immunosuppressive 
agents, fatalities are becoming rare [20].  For the diagnosis of SLE the presence of anti-
nuclear antibodies, directed against nucleic components of the cell, is strongly indicative [21, 
22].  Similar to the human disease, san/san mice develop auto-antibodies and, more 
specifically, antibodies directed against nuclear components.  Further phenotypes include 
spontaneous germinal center formation and increased numbers of TFH cells [1, 2, 23].  The 
most conspicuous molecular phenotype of san/san mice is the aberrant high expression of 
ICOS on all kind of T cells.  The increased ICOS expression contributes most significantly to 
the pathology of san/san mice [1].  Therefore, the M199R mutation interferes with Roquin’s 
function to repress ICOS, leading to T cell activation, TFH cell development, germinal center 
formation and antibody production against self-antigens (Figure 5-1, page 14).   
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Figure 5-1: Scheme of immune responses against foreign or self-antigen in wildtype mice and against self-
antigen in san/san mice.  (1) T cells are activated by foreign antigens through signal 1 and 2, ICOS 
becomes upregulated and CD4 T cells differentiate into follicular T helper (TFH) cells.  This allows the 
formation of germinal centers, in which plasma cells differentiate to produce high affinity antibodies.  (2) 
If only signal 1 is provided during recognition of self-antigens, T cells become anergic and Roquin 
suppresses ICOS (in wildtype mice).  T and B cells will not differentiate and no antibodies are produced.  
(3) After stimulation of T cells in san/san mice through signal 1 alone, Roquin M199R cannot suppress 
ICOS. T cells become activated, promote an immune response and initiate the production of antibodies 
against self. 
 
The published data show that Roquin prevents autoimmunity by limiting the inducible co-
stimulatory molecule ICOS on T cells and indicate that control of ICOS expression is one 
way to ensure that T cell activation and germinal center responses only occur against foreign 
antigens (Figure 5-1). 
It has been reported that Roquin downregulates ICOS posttranscriptionally and that miRNAs 
are involved in this process [1].  Therefore, the next sections will focus on known 
mechanisms of posttranscriptional gene silencing and will include a description of miRNA 
biogenesis and function. 
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5.3 Posttranscriptional gene regulation 
The individual amounts of proteins within a cell have to be regulated.  This is essential for 
homeostasis and many intra- and inter-cellular processes.  The quantity of a protein can be 
regulated at the level of transcription or posttranscriptionally at the level of translation or 
protein stability (Figure 5-2).   
 
Figure 5-2: Schematic representation of levels of regulation at which protein expression is affected.  
Regulation can occur at the step of mRNA transcription, protein translation (silencing) or the protein 
itself. 
 
The expression of genes is generally regulated by transcriptional activation or repression.  In a 
lengthy procedure the generated mRNA transcripts need to be translated, the polypeptides 
folded and often modified posttranscriptionally before a functional enzyme/protein is 
produced.  Cells need to be able to quickly adjust protein levels in response to endogenous or 
exogenous triggers (e.g. Ca2+ levels, starvation, etc).  This can be achieved in several ways 
without going through the whole process of transcription and/or translation, e.g. by 
phosphorylation/dephosporylation of proteins or posttranscriptional repression/de-repression 
by miRNAs.  These mechanisms are extremely important for a wide range of physiological 
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processes, including development, differentiation, reproduction and immune responses.  
Changing the level of a protein can further be achieved by specific targeting of the protein for 
degradation.  Such a mechanism is for example exerted by E3-ubiquitin ligases that conjugate 
ubiquitin to target proteins (in form of poly-ubiquitinylation), which will trigger degradation 
by the proteasom, [24].  Interestingly, E3-ubiqutin ligases are not only very important in 
many basic cellular functions [24], but seem to play a critical role in the prevention of 
autoimmune diseases [25, 26].   
Apart from regulation of protein stability, the amount of a protein is also determined by the 
half-life of its mRNA and by the extent to which its mRNA is available for translation.  
Deregulated translational repression and mRNA turnover can result in various diseases, e.g. 
cancer, inflammatory disease and Alzheimer's disease [27-31].  Consequently, substantial 
efforts are being invested to improve our understanding of the mechanisms that regulate 
mRNA turnover and efficiency of translation.   
Obviously, translational control involves several posttranscriptional procedures that share 
mRNA as a substrate [32-34].  During mRNA biogenesis, the primary transcript is processed 
by removal of introns and modified by addition of a poly(A) tail and a 5’CAP that consists of 
a modified guanine nucleotide [35].  Subsequently, the mRNA is exported from the nucleus 
into the cytoplasm for translation.  The mRNA is subject to quality control and can be 
degraded in a process known as nonsense mediated decay (NMD) [35].  NMD is a translation-
dependent process that recognizes and degrades mRNAs that contain a premature translation 
termination codon, and thereby prevents the accumulation of carboxy-terminally truncated 
proteins [36].   
The mRNAs that pass the criteria of NMD are still subject to regulation of translation and 
decay (Figure 5-2, page 15).  Many proteins are involved in the regulation of translation and 
mRNA decay.  Roquin has been proposed as a factor that promotes ICOS mRNA decay [1].  
Therefore, the next section will focus on intrinsic (cis) elements and extrinsic (trans) factors 
that control the half-life of mRNAs. 
 
5.3.1 mRNA turnover is regulated by cis-elements and trans-acting factors  
The stability of mRNAs in eukaryotes varies tremendously, with half-lifes of mRNAs ranging 
from approximately 15 minutes to more than 24 hours [37].  These differences arise on the 
one hand from cis-elements within the mRNA itself and on the other hand from trans-acting 
factors in the cytoplasm (Figure 5-3, page 17).   
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Figure 5-3: Simplified schematic representation of regulatory elements for mRNA stability.  Eukaryotic 
mRNAs contain a 5'CAP, a 5' untranslated region (5'UTR), a coding sequence (CDS), a 3'UTR and a 
poly(A) tail.  Elements (cis-elements) within the mRNA are the 5'CAP, elements within UTRs and the 
poly(A) tail.  Proteins in the cytoplasm (trans-acting factors) can influence mRNA turnover by regulating 
the 5'CAP, the Poly(A) tail or by recognizing elements in 3'UTRs. 
 
The regulation of mRNA stability is crucial for T cell responses (section 5.3); and at least 100 
mRNAs with a short half-life show differential regulation between resting and activated T 
cells [38].  Not only cytokine mRNAs, but also transcripts encoding cell surface receptors, 
proteins involved in signal transduction, transcription factors, regulators of the cell cycle and 
factors that are pro- or anti-apoptotic show extreme regulation at the level of mRNA stability 
in the process of T cell activation [38]. 
Typically, mRNAs are stabilized through their poly(A) tail and the 5'CAP [39, 40].  In fact, 
deadenylation is the first step in the decay of many mRNAs [41-43], which is then followed 
by decapping [44, 45].  mRNAs without 5'CAP and without poly(A) tail are rapidly degraded 
by 5' to 3' and 3' to 5' exonucleases as well as by endonucleases [35, 46].  Generally, the 
poly(A) tail of mRNAs is gradually shortened by exonucleases as soon as mRNAs reach the 
cytoplasm [35].  Therefore, mRNA half-life depends on the length of the poly(A) tail, except 
for replication-dependent histone mRNAs.  These mRNAs have a 3' stem-loop instead of a 
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poly(A) tail that affects the rate at which the mRNA is translated and degraded [47, 48].  Still, 
regulation of half-life for most mRNAs is achieved by controlling the 5'CAP or the poly(A) 
tail (Figure 5-3).  Examples of trans-acting factors effecting the 5'CAP or poly(A) tail will be 
mentioned later in the section.  Beforehand, some cis-elements within mRNAs that can 
regulate mRNA stability will be described here.   
Typically, gene-specific regulation via mRNA stability occurs through cis-elements in the 3' 
untranslated region (3'UTR).  For example, the 3'UTR of ICOS mRNA renders the mRNA 
sensitive for Roquin-dependent repression [1].  Regulation through the 3'UTR can even work 
independently of the remainder of the mRNA [46].  Some cis-elements in the 3'UTR of a 
number of mRNAs have been discovered in recent years.  For example, the 3'UTRs from 
mRNAs encoding ferritin and the transferrin receptor contain so-called iron response 
elements (IREs).  These mRNAs are regulated posttranscriptionally in response to changes in 
intracellular iron concentrations.  The IRE is a 23-27 base pair (bp) stem-loop that can be 
recognized by an iron regulatory protein (IRP), a trans-acting factor [46].  Another example 
for a cis-element is the U-rich region of approximately 20 nucleotides within the 3'UTR of the 
two oncogenes c-fos and v-fos.  This region promotes deadenylation and thereby mRNA 
decay [49, 50].  Additionally, the 3'UTRs of c-fos and v-fos also contain AU-rich elements 
(AREs).  In combination both cis-regulatory elements have been shown to be extremely 
potent for RNA destabilization [51, 52]. 
AREs are encoded in 3'UTRs of many mRNAs, for example in the 3'UTR of a lot of 
cytokines, such as IL-1, IFN-γ, TNF-α and IL-2, as well as immediate early genes, such as c-
myc [37, 46].  These mRNAs are among the shortest-lived mRNAs in eukaryotes [53].  The 
3'UTR of ICOS mRNA also contains three AUUUA pentamers.  However, it is not clear 
whether these AUUUA pentamers can cause destabilization of the ICOS mRNA.  The reason 
is that different AU-rich RNA sequences can function as destabilizing mRNA signals and that 
it has not been functionally tested for ICOS mRNA whether the three AUUUA pentamers can 
lead to destabilization of the mRNA.  Although it remains elusive what configuration makes 
AREs effective [46, 54, 55], AU-rich elements have been shown to be essential cis-acting 
elements for the destabilization of many mRNAs [56]. 
As mentioned above, mRNA regulation not only depends on cis-elements within the mRNA, 
but also on the presence of trans-acting factors in the cytoplasm that influence mRNA decay 
(Figure 5-3).  The next section will therefore describe some of the best known trans-acting 
factors.   
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Some trans-acting factors can destabilize mRNAs, while others function as stabilizers [46].  
The best known mRNA stabilizing proteins are the poly(A)-binding protein (PABP) and the 5' 
CAP-binding protein eIF4E [57], both being required for active translation.  Consequently, 
translation itself prevents the mRNA from degradation.  Also extensively studied were the 
RNA-binding proteins 'c-fos- and c-myc- coding region determinant-binding protein' that have 
been identified for the regulation of c-fos and c-myc, respectively [41, 46, 58].  Another 
example is the iron regulatory protein (IRP) that can bind to IREs encoded in the mRNAs of 
transferrin and ferritin and subsequently causes mRNA stabilization.   
However, reports are accumulating about trans-acting factors that can function as mRNA 
destabilizers.  Trans-acting factors can destabilize mRNAs without possessing intrinsic 
mRNase activity, like RNases [46].  Instead, they promote mRNA decay as regulatory 
proteins [46].  One important protein family of trans-acting factors are the ATP-dependent 
RNA helicases that participate in almost all pathways of RNA processing and degradation 
[59].  RNA helicases unwind secondary structures or displace bound proteins and/or RNA 
[59].  For example, it has been shown that the ATP-dependent helicase DDX6 (also referred 
to as Rck) has a key role in translation repression [60], mRNA decay [61], and general mRNA 
protein complex (mRNP) remodeling [60, 62].  Another important protein family of trans-
acting factors are the Lsm2-8 and Lsm1-7 complexes that can act as chaperones for RNA-
RNA and RNA-protein interactions [59].  The Lsm1-7-Pat1 complexes can function as 
decapping activators of the mRNA and thereby promote the degradation of mRNAs via 5'-3' 
exonucleases [63].  Similarly, the DCP1:DCP2 complex functions as a decapping activator 
and therefore promotes mRNA decay [64].  However, mRNA decay is not only promoted by 
decapping mechanisms.  Instead, deadenylation is thought to be the first step for the decay of 
most mRNAs.  The deadenylation complex CCR4-Not is therefore a central trans-acting 
factor [59, 65].  Another family of proteins, the AU-rich binding proteins (AUBPs), can also 
be considered as trans-acting factors [46].  They recognize AREs in the 3'UTR of a variety of 
mRNAs.  Examples are AUF1, HuR, KSRP and TTP [37].  AUF1, KSRP and TTP contain 
zinc finger domains that can bind nucleic acids and cause destabilization of the target mRNA 
[66, 67].  HuR is an exception that can also recognize AREs in 3'UTRs but with an RNA-
recognition motif (RRM) that leads to stabilization of the mRNA [68].  Thereby, HuR is an 
important antagonizing factor for mRNA decay pathways.  Nevertheless, Tristetraprolin 
(TTP) is the most prominent example of AUBPs, which contains CCCH-type zinc finger 
domains [69-73], similar to Roquin.  For Roquin the mechanism of translational repression 
was unclear until now, but the mechanism of TTP has been studied quite extensively.  The 
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combination of two CCCH-type zinc fingers allows TTP to bind directly to the TNF-α mRNA 
[70, 74].  TTP promotes mRNA decay by interaction with other trans-acting factors, for 
example CCR4, a component of the CCR4-Not deadenylation complex, and DCP2, a 
component of the DCP1:DCP2 decapping complex, or the 5'-3' exonuclease XrnI [75].  Many 
mRNA decay processes are functionally linked through the use of common factors or by 
being physically connected [45].   Indeed, trans-acting factors, together with their mRNA 
targets, co-localize within discrete cytoplasmic domains, known as processing bodies (P 
bodies) [45].  In support of that notion, ICOS mRNA, the target of Roquin, was reported to 
localize to P bodies [1].  However, Roquin itself has been described to localize to different 
cytoplasmic domains, known as stress granules [2], to which some other proteins involved in 
mRNA regulation can also localize [76].  Therefore, the next section will introduce P bodies 
and stress granules, and describe their function in mRNA decay.   
 
5.3.2 P bodies and stress granules are cytoplasmic loci involved in mRNA 
silencing 
Processing bodies (also called P or GW bodies) are compartments without membrane in the 
cytoplasm of eukaryotic cells.  They contain translationally inactive mRNAs as well as 
enzymes that are involved in mRNA turnover.   
P bodies were first described in 1997, showing that XRN1, the main cellular 5'-3' 
exoribonuclease, localized in discrete, prominent loci in the cytoplasm [45, 77].  This 
discovery remained unappreciated until 2002, when an autoimmune serum recognized a novel 
protein of unknown function, GW182, that stained the same compartments [78, 79]. 
The decapping activators DCP1:DCP2 [80] and Lsm1-7, Rck or the deadenylase complex 
CCR4-Not [81], all introduced in the section 5.3.1 and 5.3.3, also localize to P bodies.  The 
fact that all proteins involved in mRNA destabilization and translational repression could all 
be detected in P bodies, raised the question whether these loci are exclusively used for storage 
of translationally inactive RNAs or whether these are places at which mRNA decay actually 
occurs.  There are three strong indications that mRNA degradation takes place in P bodies 
[45].  First, P body assembly depends on the presence of RNA in the cell [82, 83].  Second, P 
bodies disappear when mRNA decay is blocked at an early stage in cells, e.g. by preventing 
deadenylation in cells [84, 85].  Third, P bodies enlarge if the progression of mRNA decay is 
blocked and intermediates accumulate [79, 80].  In spite of this, it may also be the case that 
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the P body structure itself is not required for mRNA decay [45], since P body components can 
dynamically exchange with the cytoplasmic pool [76].   
In addition to P bodies, stress granules constitute another compartment in the cytoplasm, in 
which translational repression takes place.  Many proteins involved in translational repression 
do not only localize to P bodies, but also to stress granules [76].  For example, TTP can be 
detected in P bodies, as well as in stress granules, if stress was previously induced [75, 76, 
86].  When cells are exposed to adverse conditions, such as heat shock, oxidative stress or 
energy deprivation, they initiate a stress response that involves the assembly of stress granules 
and bulk shutdown of mRNA translation [75].  Such a stress response is mediated by 
phosphorylation of the eukaryotic initiation factor (eIF) 2α [87].  The activation of one or 
more of the eIF2α kinases leads to stress granule assembly by decreasing the levels of eIF2-
GTP-tRNAMET, the ternary complex that is required for loading the initiator methionine onto 
the 48S preinitiation complex to start translation [87].  This allows binding of the RNA-
binding protein TIA-1 (T cell internal antigen-1) to the 48S complex instead of the ternary 
complex and promotes polysome disassembly and aggregation of TIA-1.  The latter leads to 
the formation of stress granules [87].  Stress response is not only a basic mechanism for cell 
survival, but is also activated during T cell differentiation to control cytokine levels, for 
example [88].  As compared to P bodies, stress granules are bigger in size.  Despite this 
obvious difference, both can be physically linked for the regulation of some RNAs [89].  
However, to which extent these two cell compartments cooperate in function or exchange 
components is not clear. 
Interestingly, components of the microRNA (miRNA) pathway, for example Argonaute 2 
(Ago2), also localize to P bodies as well as stress granules [90-92], and it has been suggested 
that miRNAs themselves are involved in the mechanism by which Roquin represses ICOS [1].  
Therefore, the biogenesis and function of miRNAs is introduced/described in the next section. 
 
5.3.3 MicroRNAs, a unique class of trans-acting factors 
MicroRNAs (miRNAs) are small (~22 nucleotide) non-coding single-stranded RNAs that 
represent a novel class of trans-acting factors that were first discovered in 1993 [93].  
miRNAs bind to partially complementary sequences in 3'UTRs of mRNAs, which causes 
translational inhibition and mRNA decay.  They repress the translation of a big part of all 
mRNAs, including critical factors for cell growth, proliferation, development and 
differentiation [94].  Consequently, deregulation of miRNAs was found to be implicated in 
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the development of diseases, such as cancer and autoimmunity.  For example, mice 
overexpressing the miR-17-92 cluster suffer from a lymphoproliferative and autoimmune 
disease that was associated with auto-antibody production [95].  Overexpression of miR-155 
in mice caused pre-B cell leukemia and B cell lymphoma [96].  miR-155 can also be found 
overexpressed in different human lymphoma, including B cell lymphoma, such as Hodgkin or 
diffuse large B cell lymphoma [94, 97].  miRNAs are transcribed as several hundred bp long 
primary miRNAs (pri-miRNAs) and are processed in the nucleus by an enzyme complex of 
Drosha/DGCR8 (Figure 5-4 step 1-2, page 23).  The resulting ~90 bp pre-miRNAs are then 
exported by Exportin-5 into the cytoplasm, where they are recognized by Dicer (Figure 5-4 
step 3-4, page 23).  Dicer processes pre-miRNAs into double-stranded miRNAs, from which 
one strand, the mature miRNA, is selectively loaded into the RNA-induced silencing complex 
(RISC) by one of the Argonaute 1-4 (Ago1-4) proteins (Figure 5-4 step 5, page 23).  This 
process is also known as miRISC formation.  Binding of RISC loaded miRNAs to sequences 
in the 3'UTR of mRNAs induces translational inhibition, followed by destabilization of the 
mRNA [98-101].  Several findings argue that P body formation itself as well as P body 
components are essential for miRNA-mediated translational inhibition (Figure 5-4 step 6, 
page 23).  First, Ago proteins and mRNAs that are targets of miRNAs accumulate in P bodies 
in a miRNA-dependent manner [92, 102, 103].  Second, GW182, a major P body component, 
interacts with Argonaute proteins and is required for miRNA-mediated repression [104, 105].  
Knockdown of GW182 or introduction of a dominant-negative mutant of GW182, interferes 
with miRNA-mediated repression and P body formation [102, 103].  And third, a helicase 
essential for general translational repression, Rck, (section 5.3.1) that also localizes to P 
bodies (section 5.3.2), has been identified to be crucial for miRNA-mediated silencing and P 
body formation [106].  In contrast to these results, there have also been reports that miRNA-
mediated silencing does not require P bodies as such.  For example, the knockdown of Lsm1, 
an enzyme involved in many mRNA decay processes (section 5.3.1) disrupts P body 
formation, but does not affect Ago2-mediated miRNA function [106].  However, another 
publication reported that Lsm1 is actually required for the repression of about 5% of miRNA-
targeted mRNAs [107]. 
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Figure 5-4: miRNA biogenesis and translational inhibition by miRNAs.  Numbers indicate steps involved 
in miRNA biogenesis, translational inhibition and mRNA decay: (1) Primary miRNAs (pri-miRNAs) are 
transcribed, (2) Drosha processes pri-miRNAs into precursor miRNAs (pre-miRNAs).  (3) Pre-miRNAs 
are exported into the cytoplasm by Exportin 5.  (4) Dicer processes pre-miRNAs into mature miRNAs.  (5) 
The mature miRNA strand gets loaded onto the RISC complex.  (6) Inhibition of translation by miRNAs 
requires the P body components Rck and GW182 and about 5% of all miRNAs also depend on Lsm1. 
 
Still, this report, and a report by Izaurralde and colleagues [45] suggest that P body formation 
is rather a consequence of translational inhibition than the cause.  Although it remains 
controversial whether P body formation is required for miRNA-mediated repression, it is now 
generally accepted that proteins located in P bodies and promoting general mRNA decay 
(section 5.3.1 and 5.3.2), such as the decapping activator complex DCP1:DCP2 and 
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deadenylation activator complex CCR4-Not, are required for miRNA-mediated silencing 
[107-110].  Actually, many translational repression or mRNA decay pathways overlap [111] 
and are poorly separated from each other in current publications.  For example, TTP does not 
seem to require the miRNA pathway, judged by most publications about TTP, but it has once 
been reported that Dicer and Argonaute proteins, as well as miR-16, are involved in the 
mechanism of TTP [112].  Similarly, Roquin-dependent ICOS repression has recently been 
proposed to critically depend on specific sequences in the ICOS 3'UTR that could be 
recognized by miR-101 [1].  However, it has not been clarified in these reports how and at 
which state TTP or Roquin actually cooperate with the miRNA pathway.  To understand these 
mechanisms and their cooperation, it seems necessary to discriminate and dissect these 
pathways genetically.  Such an attempt has not been reported so far. 
 
5.3.4 Posttranscriptional gene silencing by Roquin 
At the beginning of this research project in 2006, Roquin was portrayed as an essential factor 
in T cells for the prevention of autoimmune diseases (section 5.2).  At that point in time, the 
molecular function was completely unknown.  The RING finger domain and CCCH-type zinc 
finger of Roquin implied that Roquin could be a regulator of protein stability or mRNA 
translation.  RING finger domains can exert E3 ubiquitin ligase activity and therefore regulate 
protein levels posttranscriptionally (section 5.3).  Interestingly, other E3 ubiquitin ligases, 
such as Cbl-b and Itch also play a role in the prevention of autoimmune diseases [25, 26].  In 
fact, Rle-1, the homolog of Roquin in C.elegans, exhibits E3 ubiquitin ligase activity towards 
DAF-16, the worm homolog of Foxo3a [113].  However, it was unclear whether mammalian 
Roquin can posttranscriptionally regulate proteins and if it requires its RING finger domain 
for its activity.  The CCCH-type zinc finger domain suggests interaction with nucleic acids.  
MNAB, the paralog of Roquin, has been shown to interact with DNA in vitro, an interaction 
that partly depends on the CCCH-type zinc finger [114].  Other nucleic-acid binding proteins, 
such as TTP and Zc3h12a, also contain CCCH-type zinc fingers and can regulate mRNA 
levels posttranscriptionally [70, 115].  TTP and Zc3h12a can bind and destabilize mRNA with 
either two zinc fingers or an additional amino-terminal domain, respectively [70, 115].  It was 
unclear whether Roquin or MNAB, both containing only one CCCH-type zinc finger, can also 
regulate or bind to mRNAs.  Interestingly, Roquin and MNAB share a conserved N-terminal 
domain upstream of the CCCH-type zinc finger with so far unknown function.  It was known 
that this so-called ROQ domain bears an essential function for the prevention of autoimmune 
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diseases, because the M199R mutation in the ROQ domain of Roquin causes the disease in 
san/san mice (section 5.2).   
In 2007 it was published that Roquin regulates ICOS posttranscriptionally by promoting ICOS 
mRNA decay [1].  In agreement with this, Roquin was shown to localize to stress granules, 
further indicating that Roquin could regulate mRNA levels (section 5.3.2).  In addition, the 
publication in 2007 suggested that miRNAs are required for the repression of ICOS by 
Roquin [1].  This implied a novel mode of mRNA regulation.  However, it remained unclear 
how Roquin could exert this function and how it would cooperate with the miRNA pathway. 
To address these open questions in this project, a structure-function analysis of Roquin-
mediated ICOS repression was performed.  To do so, a panel of point- or deletion-mutants as 
well as chimeras (combining sequences of Roquin and MNAB) were generated.  Mutant and 
wildtype proteins were analyzed in their subcellular localization and tested for their ability to 
bind to ICOS mRNA and to repress ICOS expression.  Finally, a genetic dissection was 
performed using cell systems of knockdown or knockout of key molecules in translational 
repression or/and mRNA decay.  This dissection aimed to investigate a functional 
requirement or contribution of miRNAs and miRISC formation and to discriminate a 
functional involvement of the stress granule or P body pathway in Roquin-mediated ICOS 
repression. 
 
 
 
 
6.1 Antibodies 
 
Figure 6-1: Illustration of the structure of mouse Roquin and mouse MNAB.  This illustration shows 
individual RING and zinc fingers, ROQ and coiled-coil domain, as well as proline-rich regions of 
Roquin and MNAB.  Black bars indicate the regions from which peptides were synthesized and used to 
generate rat monoclonal antibodies, or the region that includes epitopes recognized by commercial 
polyclonal antibodies. 
 
Antibodies against mouse Roquin and MNAB were generated in collaboration with Elisabeth 
Kremmer's group (section 11).  Antibodies were produced by injection of BSA-conjugated 
peptides into rats:  
Q4-2 (Roquin or MNAB RSLGERTVTELILQHQNPQQLS),  
Q4-4 (Roquin NKTSSLNLSEDSEGGGDNNDSQR),  
POCO (MNAB VMSEDKNDFLKPIANGKMVNS).   
Hybridoma cells lines 5E9, 6A6, 5B11, 2F6 and 3B5 were repeatedly subcloned and effective 
antigen recognition was evaluated by ELISA and immunoblots (section 8.1.1).   
Monoclonal anti-CD3, anti-CD28, anti-IL4, anti-IFN-gamma and anti-IL-12 were purified on 
protein G sepharose columns using supernatants from 145-2C11, 37N, IIB11, Xmg-1.2 and 
C17.8 hybridomas, respectively. 
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Table 6-1 Purchased antibodies: 
Antibody Company 
Anti-mouse ICOS-PE, anti-mouse CD44-
APC; anti-human ICOS-biotin (ISA-3), 
Streptavidin-APC, Streptavidin-PE, anti-
mouse Thy1.1-PerCP or -APC and anti-
mouse CD4-APC. 
eBioscience 
Cy5-conjugated anti-mouse or anti-rabbit and 
HRP-conjugates 
Jackson Immuno Research 
primary antibodies against Roquin (514A) 
and DDX6 (461A) 
Bethyl 
Anti-GFP (A11122)  Invitrogen 
Anti-Flag-tag (M2)  Sigma 
Anti-Argonaute-2 (C34C6) Cell Signaling Technology 
Anti-Tubulin (B-5-1-2) or TIA-1 (C-20)  Santa Cruz Biotechnology 
 
6.2 Oligonucleotides 
Oligonucleotides were synthesized by the company METABION.   
Table 6-2 Primers: 
Primer name Sequence from 5' end Purpose 
Roquin Pos 900 
Forw 
GACCAGTGGTCCTCTTTGC Primer used for sequencing within 
the Roquin open reading frame. 
Roquin Pos 2300 rev GCTGCCACAACATCTTTGGG Primer used for sequencing within 
the Roquin open reading frame. 
Roquin mut1 forw GTAGTGCATGGATTGGTTGATTATATC 
CAGAACCACAGC 
Primer used to correct a mutation 
in the original cDNA clone of 
Roquin obtained from Dr.  Carola 
Vinuesa.    
Roquin mut1 rev 
 
GCTGTGGTTCTGGATATAATCAACCAATC
CATGCACTAC 
Primer used to correct a mutation 
in the original cDNA clone of 
Roquin obtained from Dr.  Carola 
Vinuesa.    
Roquin depletion away 
for 
 
GGGTACAAGCAAGCAAGCAGAAAATGG
CCAGCCCGAGCCCCC 
Primer used to correct a mutation 
in the original cDNA clone of 
Roquin obtained from Dr. Carola 
Vinuesa.    
Roquin depletion 
Away rev 
GGGGCTCGGGCTGGCCATTTTCTGCTTGC
TTGCTGCTTGTACCC 
Primer used to correct a mutation 
in the original cDNA clone of 
Roquin obtained from Dr. Carola 
Vinuesa.    
Roquin mut2 forw GGGAGGTGAACACCCTGGCAAGCCAGCC
ACAGCCCCCTTC 
Primer used to correct a mutation 
in the original cDNA clone of 
Roquin obtained from Dr. Carola 
Vinuesa.    
Roquin mut2 rev GAGGGGGCTGTGGCTGGCTTGCCAGGGT
GTTCACCTCCC 
Primer used to correct a mutation 
in the original cDNA clone of 
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Roquin obtained from Dr. Carola 
Vinuesa.    
ICOS human forw 
BamHI 
GAGAATCCGGACCATGAAGTCAGGCCTC
TGGTATTTC 
Forward primer to clone human 
ICOS cDNA.   
ICOS humanFL rev 
XhoI 
GAGCTCGAGGGTTACTACTGTTAAAATC
TCTTTG 
Reverse primer to clone human 
ICOS cDNA including its 3'UTR. 
ICOS human rev CDS 
XhoI 
GAGACTCGAGGGTTATAGGGTCACATCT
GTGAG 
Reverse primer to clone human 
ICOS containing only the open 
reading frame. 
Roq SalI ATG weg 
forw 
GAGAGTCGACCCCTGTACAAGCTCCACA
ATGG 
Primer to clone the Roquin open 
reading frame without start codon 
and 3’ to the GFP open reading 
frame. 
Roq NotI rev GAGAGCGGCCGCCTAGGGAGCAGAATTG
GAAAC 
Primer to clone the Roquin open 
reading frame. 
Roquin 2880 STOP no 
coil rev 
GGGAGAAAATGTCCATGGCAGAAGTGGC
CAGTTAAGGAAAACCCC 
Primer to insert a STOP codon in 
the Roquin open reading frame at 
position 2880 (bp) for deletion of 
the coiled-coil domain. 
Roquin 2880 STOP no 
coil forw 
GGGGTTTTCCTTAACTGGCCACTTCTGCC
ATGGACATTTTCTCCC 
Primer to insert a STOP codon in 
the Roquin open reading frame at 
position 2880 (bp) for deletion of 
the coiled-coil domain. 
RING RoquinTG-GC TCTGAGTGCAAATTGGGGCGGAAAGGAA
ATCCGTCC 
Primer to mutate cysteine at 
position 14 (aa) to alanine in 
Roquin. 
RING RoquinTG-GC GGACGGATTTCCTTTCCGCCCCAATTTGC
ACTCAGA 
Primer to mutate cysteine at 
position 14 (aa) to alanine in 
Roquin. 
Roquin 1550 STOP no 
ProlR 
GGGAGCACAGTGACACAACTGATTCCAT
GAGGGACAGACCCCAGC 
Primer to insert a STOP codon at 
position 1550 (bp) in the Roquin 
open reading frame for deletion of 
the carboxy-terminus including 
the proline-rich region.   
Roquin 1550 STOP no 
ProlF 
GCTGGGGTCTGTCCCTCATGGAATCAGTT
GTGTCACTGTGCTCCC 
Primer to insert a STOP codon at 
position 1550 (bp) in the Roquin 
open reading frame for deletion of 
the carboxy-terminus including 
the proline-rich region. 
Zinc Roq forw new GCAAATACAAAACATACATGGCTCGAGA
TATGAAGCAAAGGG 
Primer to mutate cysteine at 
position 418 (aa) to arginine. 
Zinc Roq rev neu CCCTTTGCTTCATATCTCGACCGATGTAT
GTTTTGTATTTGC 
Primer to mutate cysteine at 
position 418 (aa) to arginine. 
ICOSFL POS 896 
correct rev 
GGAGACAGGGATTCCACTCCCAGTGAGC
ACACAGGAGCTGGGC 
Primer to correct a mutation in 
full length ICOS at position 896 
(bp). 
ICOSFL POS 896 
correct for 
GCCCAGCTCCTGTGTGCTCACTGGGAGT
GGAATCCCTGTCTCC 
Primer to correct a mutation in 
full length ICOS at position 896 
(bp). 
GFP NotI  forw CACCGCGGCCGCACCATGGTGAGCAAGG
GCGAGGA 
Primer to clone GFP into 
PETOPO. 
GFP BglII XbaI rev AGATCTAGATTACTTGTACAGCTCGTCCA
TGCCGA 
Primer to clone GFP into 
PETOPO. 
Roq RINGC34A 
forwn 
CCCATCAGTTTGGGCGCTGGCCATACTGT
CTGCAAA 
Primer to mutate cysteine at 
position 34 (aa) to alanine, when 
cysteine at position 14 (aa) is 
already mutated to alanine. 
Roq RINGC34A revn TTTGCAGACAGTATGGCCAGCGCCCAAA
CTGATGGG 
Primer to mutate cysteine at 
position 34 (aa) to alanine, when 
cysteine at position 14 (aa) is 
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already mutated to alanine. 
Roquin M199R rev CAGAGCTTCCTCCTGCCTCGCTGGTCCAA
GGAACTGGC 
Primer to mutate methionine at 
position 199 (aa) to arginine. 
Roquin M199R forw TGCCAGTTCCTTGGACCAGCGAGGCAGG
AGGAAGCTCTG 
Primer to mutate methionine at 
position 199 (aa) to arginine. 
humanCD4NotIforw GAGCGGCCGCACCATGAACCGGGGAGTC
CC 
Primer to clone the human CD4 
open reading frame. 
Human CD4 BglII rev GAGATCTTCAAATGGGGCTACATG Primer to clone the human CD4 
open reading frame. 
ICOSFL POS 
1636 rev 
GAGAATGCTGCTGGCCCATTAAAGATG Primer for sequencing of human 
ICOS.   
hICOS BglII AgeI 
forw 
CACCAGATCTTAGTAATAGACCTGGTAT Primer to clone the human ICOS 
cDNA into PETOPO.   
hICOS CDS AvrII 
BamHI rev 
CCTAGGTAGTAATAGGGATCCTTATAGG
GTCACATCTGTGA 
Primer to clone only the open 
reading frame of human ICOS. 
hICOSFL 
AvrIIBamHI rev 
CCTAGGTAGTAATAGGGATCCCTTTGCCT
TCTTACTACTGTTA 
Primer to clone the human ICOS 
cDNA with its 3'UTR. 
hICOSFL XhoI till20 
bp before 
GAGACTCGAGGGTTAAGATAATATAAGT
ATGC 
Primer to clone human ICOS 
cDNA with its 3'UTR deleting the 
putative miR101 binding site. 
Roquin no RING SalI f GAGAGTCGACCATGGAGACCACTATCAA
TACGGAC 
Primer to clone the Roquin open 
reading frame without its RING 
domain.   
Roquin no ROQ forw 
new 
GAGAGTCGACCATGACAATTGCTCTCCA
GCGGACTGG 
Primer to clone the Roquin open 
reading frame without its RING 
domain. 
ICOSUTR only BglII 
forw 
CACCAGATCTTTGGCCAGTTTTCCTCAAC
T 
Primer to clone only the human 
ICOS 3’UTR into PETOPO with a 
BglII restriction site. 
ICOSUTR only XbaI 
rev 
TCTAGAGTGGCTCCTCTTAAAACTGGATT Reverse primer to clone the 
human ICOS 3’UTR into 
PETOPO with a XbaI restriction 
site 
Roquin no Nterm for GAGAGTCGACCATGGAAGAACTGGAAA
AGTTTC 
Primer to clone Roquin without 
RING, ROQ and Zinc finger 
Roquin Zinc Cys2 Ala 
forw 
GAAGCAAAGGGGAGGACGCCCTCGTGGT
GCCAGCTGTACGTTTGC 
Primer to mutate the 2nd cysteine 
(aa) 34 in the zinc finger domain. 
Roquin Zinc Cys2 Ala 
rev 
GCAAACGTACAGCTGGCACCACGAGGGC
GTCCTCCCCTTTGCTTC 
Primer to mutate the 2nd cysteine 
(aa) 34 in the zinc finger domain. 
Roquin Pos1280 BssSI 
MNAB comp: 
 
CAAAGGGGAGGATGCCCACGAGGTGCCA
GCTGTACGTTTGC 
 
 
Primer to generate Roquin/MNAB 
chimeras with a BssSI restriction 
site introduced into the Roquin 
cDNA. 
Roquin Pos 1280 
BssSI MNAB comp: 
GCAAACGTACAGCTGGCACCTCGTGGGC
ATCCTCCCCTTTG 
Primer to generate Roquin/MNAB 
chimeras with a BssSI restriction 
site introduced into the Roquin 
cDNA. 
AGO2 Pos 470 F-V 
forw 
 
CG GAA GTC CAT CTG AAG TCC GTC 
ACA GAG CAG CTC AGA AAG 
Primer to mutate position 470 (aa) 
phenyl-alanine to valine together 
with position 505 (aa) in the 
GW182 binding site. 
AGO2 Rev 470 F-V CTT TCT GAG CTG CTC TGT GAC GGA 
CTT CAG ATG GAC TTC CG 
Primer to mutate position 470 (aa) 
phenyl-alanine to valine together 
with position 505 (aa) in the 
GW182 binding site. 
AGO2 Pos 505 F-V 
forw 
CG GAC AGC GTG GAG CCC ATG GTC 
CGG CAC CTG AAG AAC ACG 
Primer to mutate position 505 (aa) 
phenyl-alanine to valine together 
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with position 470 (aa) to mutate 
the GW182 binding site. 
AGO2 Pos 505 rev CGT GTT CTT CAG GTG CCG GAC CAT 
GGG CTC CAC GCT GTC CG 
Primer to mutate position 505 (aa) 
phenyl-alanine to valine together 
with position 470 (aa) to mutate 
the GW182 binding site. 
Roquin forw PCR GAGAGCGGCCGCCTAGGGAGCAGAATTG
GAAAC 
 
Primer to clone Roquin open 
reading frame.   
Roquin rev PCR GAGATGATCACTAGGGAGCAGAATTGGA
AAC 
Primer to clone Roquin open 
reading frame.   
 
6.3 Expression constructs 
Expression constructs were generated by the following principle:  
First, primary constructs were generated.  For that, the open reading frame of the gene of 
interest was PCR amplified and cloned into so-called entry vectors (Invitrogen), which 
contain a gateway cloning cassette (see below).  Then secondary expression constructs, also 
containing the gateway cloning cassette, were generated by a lambda recombination reaction 
(section 7.3.5), which leads to an insertion of the open reading frame into the expression 
construct. 
  
6.3.1 Generation of primary constructs 
The open reading frames of mouse Rc3h1 (Roquin) (AY948287), human RC3H2 (MNAB) 
(NM_001100588), human ICOS including the 3’UTR (NM_012092) or human 
Argonaute 2 (NM_012154) were PCR-amplified, ligated into cloning vectors (pENTR11, 
pCR8-GW or pENTR-D Topo) and sequenced (primary vectors).  Mutations originating from 
provided vectors or introduced by PCR-amplification were corrected by site-directed 
mutagenesis using the XL Quickchange kit (section 7.3.3).  All intentionally inserted point-
mutations were generated in the same way (section 7.3.3).   
 
The following Roquin constructs were generated and verified by sequencing: 
For orientation purposes see Figure 6-2. 
Deletion-mutants of Roquin constructs with and without GFP-tag: 
-Roquin aa 1-951 
-Roquin aa 1-509 
-Roquin aa 55-1130 
-Roquin aa 338-1130 
-Roquin aa 441-1130 
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Figure 6-2: Schematic depiction of the structure of Roquin.  It shows individual domains, as well as the 
proline-rich region.  Lines indicate the regions, which were fused to generate chimeras.  Numbers refer to 
amino acid end points of the generated deletion-mutants. 
 
Point-mutants of Roquin without tag: 
-Roquin C14AC34A 
-Roquin M199R 
-Roquin C419RC428R 
 
Additional constructs: 
-Roquin-WT and 
-Roquin/MNAB chimeras  
(The conserved amino-termini of Roquin and MNAB were exchanged.  To clone these 
constructs in frame, I made use of a conserved BssSI restriction site, which -for cloning 
purposes- was present in the wrong orientation.  Therefore, I first changed this BssSI site by 
point-mutagenesis in Roquin without modifying the reading frame (Figure 6-3). 
 
 
Figure 6-3: Alignment of human MNAB and mouse Roquin open reading frames.  Black bars indicate 
regions of identity.  The BssSI site used for fusion of open reading frames and generation of chimeras is 
indicated. 
 
The following ICOS constructs were generated and sequence-verified: 
-ICOS cDNA including the 3'UTR (1-2539) and without the 3'UTR (1-600)  
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-ICOS cDNA including the  3'UTR, but deleted in the putative miR-101 binding site (1-2211) 
-the 3'UTR of ICOS (601-2539) fused 3' to the coding region of GFP or human CD4 
 
The following Argonaute 2 constructs were generated and sequence-verified: 
-the open reading frame of human Argonaute 2  
-the open reading frame of human Argonaute 2 F470V/F505V 
 
6.3.2 Generation of secondary constructs  
Secondary expression constructs were produced via lambda recombination (LR) (Invitrogen) 
(section 4.3.5) using pLNCX2, pKMV-IRES-GFP or pMSCV-IRES-Thy1.1 retroviral vectors 
or the adenoviral expression vector pCAGAdDu.  The map of the KMV vector is shown 
below to illustrate the backbone of a retroviral vector (Figure 6-4). 
 
Figure 6-4: Schematic depiction of the destination vector KMV.  LTR: long terminal repeats.  These are 
retroviral promoters that encode all sequences for gene regulation including enhancer, promoter, 
transcription initiation, transcription termination and polyadenylation signals.  Moloney MLV: Moloney 
murine leukemia virus.  LacZ alpha: the first gene of the lac operon for colony selection.  AmpR: 
ampicillin resistance.  IRES: Internal ribosome entry site, the ribosome binds CAP-independently on the 
same RNA and translates a second protein (e.g. GFP or Thy1.1 (in the case of the MSCV-IRES-Thy1.1 
vector) which is a glycosylphosphatidylinositol (GPI) anchored protein that is rapidly expressed on cell 
surfaces).  CmR: chloramphenicol-resistance.  ccdB: potent- death gene for cells that do not contain a 
ccdB gene.  Gateway recombination sites(attR1 and attR2): lambda recombinase recognition sites for LR 
reaction (section  4.3.5) to insert the gene of interest. 
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6.3.3 Constructs generated for dual luciferase activity measurements  
Adenoviral plasmids for dual luciferase activity assays were cloned based on the psiCHECK2 
dual luciferase construct (Promega), in the context of an adenoviral backbone of pAd-Pl 
(Invitrogen).  A gateway cassette was placed between the renilla luciferase open reading 
frame and the polyadenylation signal.  Hoxc8 or ICOS 3’UTRs were inserted by LR reaction 
(section 7.3.5).  The adenoviral pCAGAdDu vector was constructed by insertion of a gateway 
cassette, an internal ribosome entry site (IRES), the open reading frame of green fluorescent 
protein (GFP) and the bovine growth hormone polyadenylation sequences in the context of a 
CMV early enhancer and chicken beta-actin (CAG) promoter. 
 
6.4 Knockdown sequences 
The double-stranded oligonucleotide used to knockdown the mouse CD4 protein was inserted 
into a modified pSuper-retroviral vector that co-expresses the H1 promoter-transcribed 
hairpins independently from the human CD25 mRNA, which is driven by a mouse PGK 
promoter.   
Adenoviral knockdown vectors expressed hairpins from a U6 promoter and co-expressed GFP 
independently from a mouse PGK promoter (purchased from Sirion GmbH). 
The selected sequences were: 
Sh-mCD4:   ACAAAGAGGTGTCCGTACA 
Sh-mLsm1:    CCTCACACATTGACCAGAGTA  
Sh-mRck:   GCCAAGAACTATGTCTTTATA  
Sh-Rc3h1:   CGCACAGTTACAGAGCTCATT 
Sh-a stop cassette   TTTTTGGCCTTTTTTAGCTG  
Sh-scrambled sequence:  ACAAGATGAAGAGCACCAA  
Sh-GFP:    CAACAGCCACAACGTCTAT 
 
6.5 Cell lines 
HEK293A, HEK293T cells and NIH3T3 cells were purchased from ATCC.  Dicer wildtype 
and knockout mouse embryonic fibroblast (MEF) clones were selected after immortalization 
in culture (section 8.1.3).  MEF cells deficient in Argonaute 2 or TIA-1 and ES cells deficient 
in Argonaute 1-4 were obtained from research groups mentioned in section 11 
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6.6 Mice 
Mice were housed in a specific pathogen-free barrier facility and used in accordance with 
institutional, state and federal guidelines.  BALB/c and DO11.10 mice were obtained from 
Taconic farms and sacrificed at 6-12 weeks of age.  DO11.10 CarΔ1 mice are transgenic for 
the DO11.10 T cell receptor that is specific for a chicken ovalbumin (OVA) peptide -amino 
acids 323-339- presented by the MHC class II molecule I-Ad.  CD4 T cells from these mice 
express this TCR at high frequency (≥96%) and are therefore naive, but can be activated 
through the peptide in vitro or in vivo.  Additionally, they express a signaling-inactive version 
of the human coxsackie adenovirus receptor and are therefore permissive for adenoviral 
infection [116].  C57BL/6 Dicer fl/fl mice were bred with BALB/c CarΔ1 and C57BL/6 CD4 
Cre mice to obtain T cells deficient in Dicer that can be manipulated with adenoviral 
infection. 
 
6.7 Chemicals, enzymes, devices and cits. 
Table 6-3 Devices: 
Device Official name and Company 
Agarose gel 
chambers Peqlab Biotechnologie GmbH 
Bacterial incubator 
Brutschrank BINDER BF 53 (Binder Labortechnik) 
Innova 4400 incubator shaker (New Brunswick Scientific 
GmbH) 
CO2 incubator Forma Direct Heat CO2 Incubator HEPA Class 100 (Thermo Electron Corporation) 
FACS machine BD FACS Calibur Flow Cytometer (BD Biosciences) 
Ice machine Scotsman AF 200 (Scotsman Icesystem) 
Accuracy weighing 
machine 
KERN ABJ-220-4M (Kern und Söhne GmbH) 
KERN EW 220-3NM (Kern und Söhne GmbH) 
Confocal microscope Type: 301-185.104-000 Order-No: 500277 (Leica) 
Fluorescence 
microscope Axiovert 200M (Zeiss) 
Gel documentation (Peqlab Biotechnologie GmbH) 
Magnet stirrer  RCT basic safety control (IKA) 
Microscope Axiovert 40C (Zeiss) 
Microwave Bosch 
pH meter pH-Meter inoLab® pH 720 (Wissenschaftlich Technische Werkstätten) 
Coasting mixer Tube Roller-Mixers, SRT1 (Stuart) (ScienceLab) 
Energy supplier Stromgeber EC105 (Thermo Electron Corporation) BioRad energy supplier (BioRad) 
Spectro photometer Eppendorf BioPhotometers (Eppendorf) 
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Thermo Scientific NanoDropTM 1000 Spectrophotometer 
(Thermo Fisher Scientific Inc.) 
Sterile-working 
bench  BDK, Luft und Reinraumtechnik 
Thermo cycler 
Biometra TGradient Thermal Cycler 96 (Biometra) 
DNA Engine 48/48 Dual Alpha Unit With Two Heated Lids 
(BioRad) 
Light Cycler 480II (Roche) 
Thermo mixer Thermomixer compact (Eppendorf) Thermomixer comfort (Eppendorf) 
Table centrifuge Centrifuge 5415D (Eppendorf) Centrifuge 5417R (Eppendorf) 
UV-lamp Transilluminator model.  TS-40 (Ultra-Violet Products Ltd.) 
Vortexer Vortex Genius 3 (IKA) 
Protein gel chamber BioRad 
Blotting chamber BioRad 
Water-bath WB7 (Memmert) 
Centrifuges 
und 
Rotors 
Beckman Coulter Avanti-J-26XP (Beckman Coulter) 
JS-7.5 Swinging-Bucket Rotor (Beckman Coulter) 
JA-10 Rotor, Fixed Angle (Beckman Coulter) 
Allegra®X-12R Centrifuge (Beckman Coulter) 
Rotor FX 6100 (Beckman Coulter) 
Rotor SX 4750 (Beckman Coulter) 
 
Table 6-4 Chemicals: 
Chemical Company 
-Mercaptoethanol 99% Sigma-Aldrich 
0,05% Trypsin/ 0,02% EDTA in PBS Pan biotech GmbH 
1 kb Plus DNA Ladder Invitrogen 
Ampicillin  Roche 
Biozym DNA Agarose Biozym Scientific 
GmbH 
Brefeldin A Sigma-Aldrich 
BSA (Albumin Fraktion V) Roth 
Chloroform min.  99% Sigma-Aldrich 
dATP (100 mM) Fermentas 
dCTP (100 mM) Fermentas 
dGTP (100 mM) Fermentas 
Dimethyl Sulphoxide (DMSO)Hybri-
Max 
Sigma-Aldrich 
dTTP (100 mM) Fermentas 
Ethidium bromide 1% (w/v) Serva 
FuGene® HD Transfection Reagent Roche 
Glycogen blue Ambion 
Kanamycin sulfate Roth 
Paraformaldehyde Sigma-Aldrich 
Saponin VWR International 
GmbH 
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Tri®Reagent Invitrogen 
Trypton Merck 
Milk powder Roth 
Yeast Extract Serva 
 
Table 6-5 Enzymes: 
Enzyme Company 
Gateway LR Clonase II Enzyme Mix Invitrogen 
Herculase® II Fusion DNA Polymerase (40 
reactions) 
Stratagene 
iProofTM High Fidelity DNA Polymerase (2U/µl) Bio-Rad 
Proteinase K Invitrogen 
T4 DNA Ligase ( 10.000 U/ml) 
New England 
Biolabs 
Taq Polymerase (5.000 U /ml) 
New England 
Biolabs 
Topoisomerase I (E.coli) (5.000 U/ml) 
New England 
Biolabs 
Restriction enzymes 
New England 
Biolabs 
 
Table 6-6 General buffers (otherwise mentioned in the corresponding method-section): 
Buffer Contents 
5x TBE 45 mM Tris-HCl, 1 mM EDTA pH 8.0 
10x TE 100 mM Tris/HCl pH 8.0, 10 mM EDTA pH 
8.0 
6x DNA dye 0.25 % bromophenol blue, 0.25 % xylene 
xyanol, 30% glycerol 
TAC 13 mM Tris, 140 mM NH4Cl, pH 7.2 
PBS 137 mM NaCl, 10 mM phosphate, 2.7 mM 
KCl 
 
Table 6-7 Kits: 
Kit Company 
peqGOLD Plasmid Miniprep Kit I PeqLab Biotechnologie GmbH 
Nucleobond®Xtra Maxi Kit Macherey-Nagel GmbH & Co.  
KG 
QIA®PCR purification Kit Qiagen 
QIA®quick gel extraction Kit Qiagen 
pENTR/D-TOPO Cloning Kit Invitrogen 
GW8/-TOPO Cloning Kit Invitrogen 
Dynabeads®Mouse CD4 (L3T34) 
Kit  Dynal Biotec. 
CD4+ T cell Isolation Kit (mouse) Miltenyi Biotec. 
XL QuickChange Stratagene 
TaqManMicroRNA Assay Applied Biosystems 
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7.1 Bacterial culture 
7.1.1 Amplification and storage of bacteria 
LB media and LB agar were prepared with 'ready to mix' powder (SERVA), supplemented 
with ampicillin (100 µg/ml), spectinomycin (50 µg/ml) or kanamycin (30 µg/ml) for the 
selection of bacterial resistance.  Single colonies were scraped off LB agar plates and a fresh 
overnight bacterial culture was used for storage at -80°C, mixed at an 1:1 ratio with glycerol. 
 
7.1.2 Transformation of bacteria 
Chemical competent DH5alpha (Invitrogen) were thawed on ice.  0.5 µg plasmid were added 
followed by 15 min of incubation on ice.  A heat shock was performed at 42°C in a water-
bath for 30 s.  Thereafter cells were placed on ice for two minutes.  After shaking the cells at 
400 rpm and 37°C for one hour in 300 µl LB media, the cell suspension was spread out onto 
an LB agar plate and incubated at 37°C over night.  Single colonies were selected for 
downstream applications. 
 
7.2 Cell-culture and viral infection of mammalian cells 
7.2.1 Preparation and expansion of primary T cells 
Peripheral CD4 T cells were isolated from spleen and lymph nodes using anti-mouse CD4 
Dynabeads (Invitrogen).  Isolated CD4 T cells were kept in T cell medium (below).  T cells 
were stimulated for 36-48 hours on goat anti-hamster IgG-coated plates with anti-CD3 (0.1 
µg/ml) and anti-CD28 (1.0 µg/ml), supplemented with anti-IL-4 (10 µg/ml) to induce Th1 
differentiation.  For Th2 differentiation conditions, anti-IL-12 (3 µg/ml), anti-IFN-gamma 
antibodies (5 µg /ml) and murine IL-4 containing supernatants from I3L6 cells (equals 1000 
U/ml recombinant IL-4) were added.  After stimulation for 48 hours, cells were expanded in T 
cell media containing 10 U/ml recombinant human IL-2 (provided by the WHO, NIBSC).  
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Primary cells can be kept in cell culture for about five days after stimulation or even another 
week, if a second stimulation has been carried out. 
 
T cell medium: 
RPMI media  
10% fetal calf serum (FCS) 
0.1 mM beta-mercapto-ethanol 
100 U/ml penicillin-streptomycin 
10 mM HEPES 
 
(Suppliers are listed in section 7.2.2) 
 
7.2.2 Cell-culture conditions 
HEK293 cells and MEF cells were grown in DMEM medium (see below).  Embryonic stem 
(ES) cells were grown in ES cell DMEM medium on feeder cells and passaged twice on 0.1% 
gelatine prior to infection. 
 
DMEM medium (suppliers listed below): 
DMEM 
10% FCS 
1000 U/ml penicillin-streptomycin 
10 mM HEPES 
 
ES cell DMEM medium (suppliers listed below): 
DMEM  
20% FCS 
2 mM L-glutamine 
100 U/ml penicillin-streptomycin 
1 mM sodium pyruvate 
0.1 mM non-essential amino acids (NEAA) 
0.1 mM ß-mercapto-ethanol 
2000 U/ml leukemia inhibitory factor (LI)F 
 
Table 7-1: Medium and suppliers: 
Medium Company 
Dulbecco's Modified Eagle Medium 
(DMEM) 
Gibco, Invitrogen 
RPMI 1640, without L-glutamin BioWhittaker, 
Lonza 
 
Methods   39 
Table 7-2: Additional ingredients: 
Additive for medium Company 
100x NEEA BioWhittaker, 
Cambrex 
fetal calf serum (FCS) BioWhittaker, Lonza 
fetal calf serum (FCS) Gibco, Invitrogen 
GIBCO™ L-Glutamine-200 mM (100x), 
flüssig 
Gibco, Invitrogen 
GIBCO™ MEM Vitamin Solution (100x), 
flüssig  
Gibco, Invitrogen 
HEPES (1M) Gibco, Invitrogen 
Sodium pyruvate (100 mM) BioWhittaker 
LIF Provided by Marc-
Schmidt-Supprian 
PenStrep (10 000 U/ml) Gibco, Invitrogen 
 
7.2.3 Storage of cells 
Stocks from cell lines can be stored in liquid nitrogen in a mixture of 90% fetal calf serum 
(FCS) and 10% DMSO.  107 cells were taken up in 1.2 ml of 90% FCS and 10% DMSO, 
transferred into 2 ml freezing tubes (NUNC) and placed into a -80°C freezer over night.  The 
special isopropanol isolation of the freezing box allows a slow adjustment of the cells to the 
temperature in order to minimize the generation of ice crystals, which are detrimental to the 
cells.  Next day, the cells were transferred into a liquid nitrogen container for long-time 
storage.  Reculturing of the cells is done by thawing in a water-bath at 37°C and transfer into 
pre-warmed fresh cell-culture medium. 
 
7.2.4 Transfection of cells with FuGene HD or the calcium phosphate method 
Transfection of cells with FuGene HD: 
HEK293A cells were transfected with FuGene HD according to the manufacturer's protocol.  
Cells were counted one day prior to transfection and plated with 6 x 105 cells in the volume of 
1 ml into one well of a six well plate.  The following day transfection was performed using a 
mixture of 2 µg total DNA, 6 µl FuGene HD and 100 µl OPTI-MEM medium (Gibco).  The 
cells were used for analysis after ~24 hours. 
 
Transfection of HEK293T cells by the calcium phosphate method: 
Cells were counted one day prior to transfection and plated out using a concentration of 3x105 
cells/ml in a volume of 17 ml in a 15 cm-diameter cell culture dish.  The next day cells were 
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transfected with co-precipitates  of DNA and calcium phosphate.  To produce co-precipitates 
a mixture of 25 µg total DNA, 1.1 ml sterile water and 125 µl cold 2 M CaCl2 (stored at 
-20°C) was slowly vortexed in a 50 ml falcon tube.  1.25 ml of 2xHBS (freshly thawn) was 
added drop-wise.  The solution was incubated for 15 minutes at room temperature and 
thereafter added drop-wise to the HEK293T cells.  Transfected cells were analyzed one day 
later or kept in culture for two additional days if used for retroviral amplification (section 
7.2.6).   
 
2x HBS-stock solution: 
8.0 g NaCl 
6.5 g HEPES (260.29 MW) 
10 ml Na2HPO4 stock solution 
(Na2HPO4 stock solution: 5.25 g Na2HPO4 in 500 ml of water) 
adjusted pH to 7.0 at room temperature; aliquoted and stored at -20°C 
 
7.2.5 Confocal microscopy 
For confocal microscopy HEK293A cells were counted 24 hours prior to transfection, 
adjusted to 5x104 cells in 100 µl medium and grown on sterile glass slides in a 12 well dish 
for one hour.  Then 1 ml medium was added.  The next day, transfection with FuGene HD 
followed (section 7.2.4).  Another day later, the cells were fixed with 4% (w/v) 
paraformaldehyde and washed three times with IF-wash-buffer (below).  Staining was carried 
out using primary antibodies (1:100 for hybridoma supernatants, and 1:1000 for anti-Roquin 
and to 1:2000 for anti-Rck purchased antibodies) and secondary Cy5-coupled anti-mouse or 
anti-rabbit antibodies (1:200) all of which were diluted in IF-wash-buffer.  DAPI staining 
followed for 1 min in DAPI solution (below).  Microscopy was performed in self-made 
mounting medium (below). 
CD4 Th2 cells were infected with an adenovirus encoding GFP-tagged Roquin.  The cells 
were immobilized by using poly-L-lysine (2 ug/ml Sigma) coated glass slides and fixed with 
4% paraformaldehyde, stained with DAPI and analyzed as previously described. 
 
IF-wash-buffer: 
Phosphate buffered saline (PBS) 
0.5 % (v/v) NP-40 
0.01% (w/v) sodium-azide 
10% (v/v) FCS 
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DAPI solution:   
15 µg DAPI (Sigma D8417)/ 100 ml 2X SSC buffer  
 
20X SSC for DAPI solution:  
0.3 M Na3C3H5O(CO2)3 H2O 
3 M NaCl  
ad to 100 ml with H2O 
adjust to pH 7 
 
Mounting medium: 
Glycerol was mixed with equal parts w/v of 2x PBS and was adjusted to 0.1% n-propyl 
gallate (Sigma) final concentration.   
 
7.2.6 Production of and infection with retro- and adenovirus 
Type 5 replication-deficient adenoviruses were produced by calcium phosphate transfection 
of PacI-digested adenoviral vectors into HEK293A cells.  The viruses were amplified in 
HEK293A cells and viral stocks were purified using mini columns according to the 
manufacturer's instructions (Cell Biolabs).  Titers were determined in A549 cells by FACS 
approximately 40 hours after transduction.  ES or MEF cells (1 × 106) were transduced with 
recombinant viruses at an multiplicity of infection (MOI) of 100.   
Retroviral supernatants were produced by calcium phosphate transfection of amphotropic 
packaging vectors and retroviral expression vectors into HEK293T cells.  Supernatants were 
collected 72 hours post transfection, passed through 0.45 µm filters, mixed with polybrene at 
a final concentration of 5µg/ ml and added to MEF cells, which were spin-infected at 900g for 
1 hour at room temperature.  The medium was replaced after 24 hours and transduced cells 
were analyzed three days post infection.   
 
7.2.7 FACS-analysis 
For flow cytometry analysis of adherent cells, cells were scraped off the plates using a 
mixture of 30% cell-dissociation solution and 70% PBS and thereafter stained in FACS buffer 
(below) for 20 min on ice.  For the analysis of ICOS surface expression on CD4 cells, cells 
were stained two days after stimulation (section 4.2.1) in FACS buffer for 20 min on ice.   
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Flow cytometry was performed on a FACS Calibur device (Becton Dickinson) and raw data 
were analyzed with Flow Jo (Treestar) software.  Antibodies used for FACS analysis are 
listed in section 6.1. 
 
FACS buffer: 
PBS, pH 7.4 
1% FCS 
0.01% of sodium azide 
 
Saponin-buffer: 
PBS, pH 7.4 
0.5% saponin 
1% BSA 
 
7.3 Techniques for handling nucleic acids 
7.3.1 PCR for genotyping and generation of constructs 
 
PCR for genotyping Dicer alleles was performed with Taq Polymerase (Biolabs) according to 
the manufacturer's protocol: 
Primers that recognize wildtype and floxed alleles: 
F1: ATTGTTACCAGCGCTTAGAATTCC 
R1: GTACGTCTACAATTGTCTATG 
 
Primers that recognize Cre deleted Dicer alleles: 
F1: TCGGAATAGGAACTTCGTTTAAAC  
R2: GTACGTCTACAATTGTCTATG 
 
The PCR program for genotyping Dicer alleles: 
Segment Cycles Temperature Time 
1 1 94°C 3 min 
94°C 0.5 min 
58°C 0.5 min 
2 30 
 
72°C 0.75 min 
3 1 72°C 10 min 
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PCR procedure to produce new constructs: 
For the generation of new constructs, a combination of 1 µl Taq Polymerase (Invitrogen), for 
the generation of A-overhangs, and 0.3 µl Vent proofreading polymerase (Biolabs), to 
increase proofreading, was used.  PCR was performed according to the manufacturer's 
protocol of the Taq polymerase from Invitrogen.  Most primers were designed to match an 
annealing temperature of 58°C (section 6.2).  PCR products were loaded onto an agarose gel, 
the desired bands were dissected and subsequently extracted from the gel (Qiagen).  The pure 
PCR products were then ligated into TOPO cloning vectors (Invitrogen) according to the 
manufacturer's protocol. 
 
7.3.2 Preparative plasmid purification 
Cost-saving plasmid purification from 3-5 ml bacterial culture: 
Resuspension, lysis and neutralization buffers for this technique were taken from the MAXI 
kit of Macherey-Nagel.  Bacteria of a 3 ml overnight culture were pelleted by centrifugation 
at 14 000 g for five min.  Cells were resuspendend in 100 µl resuspension buffer and lyzed in 
200 µl lysisbuffer for five min.  Neutralization was carried out by adding 150 µl 
neutralization buffer.  After centrifugation at 14 000 g for 5 min at room temperature the 
supernatant was transferred into a new tube.  DNA was then precipitated using 100% ethanol.  
Centrifugation took place at 14 000 g for 10 min at room temperature.  After disposal of the 
supernatant, the DNA pellet was washed with 75% ethanol with subsequent centrifugation at 
14 000 g for 5 min at room temperature.  The DNA pellet was air-dried for 5 min and taken 
up in 30 µl TE buffer (see below).  The quality of DNA allows to perform restriction digests 
and lambda recombination reactions. 
 
Plasmids used for sequencing and further cloning techniques were purified with the 
peqGOLD Plasmid Miniprep. 
 
TE buffer: 
10 mM Tris-HCl, pH 7.5 
1 mM EDTA 
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7.3.3 Site-directed mutagenesis  
All point-mutations were introduced by site-directed mutagenesis using the XL Quick Change 
kit (Stratagene).  Primers (section 6.2) were chosen and the reaction mix was prepared 
according to the manufacturer's protocol.  The protocol for the PCR reaction was slightly 
altered to increase the number of colonies: 
 
Table 7-3 Program for QuickChange thermocycler:  
Segment Cycles Temperature Time 
1 1 95°C 1.2 min 
95°C 1 min 
60°C 1 min 
2 18 
 
68°C 1.1 min 
3 1 68°C 7 min 
 
The PCR product was DpnI digested for one hour and then 5 µl of the PCR product were 
transformed into competent DH5α cells.  Some of the resulting colonies were selected for 
sequencing 
 
7.3.4 Ligation of DNA fragments 
First, restriction digests of 10 µg plasmid and 10 µg insert were performed at 37°C, over night 
(total volume 45 µl), using the required enzymes (New England Biolabs) and buffers, 
according to the manufacturer's protocol.  Second, gel extraction (Qiagen) and ligation of the 
fragments with T4 DNA ligase (New England Biolabs) took place overnight at 16°C and 
according to the manufacturer's protocol. 
 
7.3.5 Lambda recombination reaction  
The lambda recombination (LR) reaction allows to transfer DNA fragments of interest 
between different vectors while maintaining the reading frame.  This system, also known as 
gateway cloning system, is a technique developed by Invitrogen.  Entry clones contain the 
gene of interest, which is flanked by attL1 and attL2 sites.  Destination vectors contain a death 
gene (ccdB), which is also flanked by attR1 and attR2 sites.  The LR recombinase recognizes 
the attL and attR sites and performs a recombinant reaction.  Different destination vectors are 
available for different purposes.  The destination vectors used in this thesis are mentioned in 
section 3.3.  During the LR reaction, the entry clone is mixed with the destination vector of 
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interest and the LR recombinase.  Only destination vectors that have recombined are selected.  
This is ensured by differences in antibiotic resistance between the destination and entry vector 
and the expression of a death gene (ccdB) in clones that have not recombined.  LR reactions 
carried out for the purposes of this thesis were performed according to the manufacturer's 
protocol. 
 
7.3.6 RNA-immunoprecipitation (RNA-IP) 
HEK293T cells (5 x 106 cells) were transfected with expression vectors and harvested for the 
RNA-IP two days later.  The cells were washed twice with PBS and crosslinked in 10 ml 
crosslinking-buffer (below) on a roller mixer for 10 min at room temperature.  Crosslinking 
reactions were quenched with glycine (pH 7.0) at a final concentration of 0.25 M for 5 min.  
The cells were centrifuged at 300 g for 5 min, followed by a PBS wash and resuspension in 
1 ml RIP-lysis-buffer (below).  Three rounds of sonification at 15% amplitude (Branson 
Digital Sonifier) in an ice-water bath for 30 s followed.  Insoluble material was removed by 
centrifugation at 16 000 g for 10 min at 4°C.  Unspecific binding of RNA to magnetic Protein 
G Dynabeads (Invitrogen) was reduced by pre-clearance of the cell lysates by mixing it with 
15 µl Protein G Dynabeads for 1 h at 4°C.  100 µl of the precleared lysate was used as an 
input control and the remainder was incubated together with 25 µl GFP antibody-coated 
Protein G Dynabeads and 20 units of RNasin (Promega) for two hours at room temperature.  
The beads were washed five times with 1 ml of high-stringency-buffer (below) and incubated 
on a roller mixer for 10 min at room temperature.  The beads containing the 
immunoprecipitated samples were collected and resuspendend in 100 µl of resuspension 
buffer (below).  Resuspended beads were incubated at 70°C for 45 min to reverse 
crosslinking.  The RNA present in the immunoprecipitations and inputs was extracted with 
Trizol reagent (section 7.3.7) and cDNA synthesis was performed with the QuantiTect 
Reverse Transcription kit (Qiagen) according to the manufacturer's protocol. 
PCR amplification (28 cycles) was carried out at an annealing temperature of 56 °C and using 
the following primers:  
ICOS-3'UTR F1: GTCAAAATGGTCCCCATCAG, R1: TTTCCAGGCTGTGTGGTTTT;  
5S-rRNA F1: GTCTACGGCCATACCACCCTG , R1: GCCTACAGCACCCGGTATTCC. 
 
 
Methods   46 
Crosslinking-buffer: 
PBS, pH 7.4 
1% (v/v) formaldehyde (Sigma) 
 
RIP-lysis-buffer: 
50 mM Tris-HCl, pH 7.5 
1% (w/v) NP-40  
0.1% (w/v) sodium deoxycholate  
0.05% (w/v) SDS  
1 mM EDTA  
150 mM NaCl 
Complete protease inhibitors mix (Roche) 
1 mM DTT 
 
High-stringency-buffer: 
50 mM Tris-HCl, pH 7.5  
1% (v/v) NP-40  
0.1% (w/v) sodium deoxycholate 
0.05% (w/v) sodium dodecyl sulfate  
1 mM EDTA  
0.5 M NaCl 
1 M urea 
1 mM DTT  
0.2 mM PMSF 
 
Resuspension-buffer: 
50 mM Tris pH 7.0 
5 mM EDTA 
10 mM DTT 
1% (w/v) SDS. 
 
7.3.7 Extraction of genomic DNA and cellular total RNA from eukaryotic cells 
Proteinase K digest of mouse tails or eukaryotic cells for genotyping: 
107 cells or 0.5 cm of each mouse tail were lyzed in 200 µl proteinase K-containing 
genotyping-buffer (below) and shaken overnight at 800 rpm and 55°C.  Proteinase K was 
heat-inactivated at 95°C for 15 min the next day.  300 µl water was added and 0.5 µl were 
then used as template for PCR. 
 
Genotyping-buffer: 
100 mM Tris-HCl, pH 8.5 
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5 mM EDTA 
0.2% SDS 
200 mM NaCl 
fresh 0.2 mg/ml proteinase K 
fresh 0.2 mg/ml protease K 
 
Extraction of cellular RNA: 
For the isolation of total RNA from immunoprecipitation samples the MirVana kit (Ambion) 
was used according to the manufacturer's instructions.  For other applications the Tri reagent 
(Sigma) was applied as follows: Harvested cells were lyzed in 1 ml of Trizol by pipetting up 
and down six times and incubated for 5 min at room temperature.  200 µl of chloroform were 
added and samples were first vigorously shaken and then incubated at room temperature for 2 
min.  The organic and aqueous phases were separated by centrifugation at 12 000 g for 15 min 
at 4°C.  The aqueous phase was transferred into fresh 1.5 ml tubes and precipitated with 500 
µl isopropanol in the presence of  1 µl Glycoblue-carrier (Ambion).  Precipitated RNA was 
collected by centrifugation at 12 000 g for 10 min at 4 °C and removal of the supernatant.  
The resulting pellet was then washed with 1 ml 75% (v/v) ethanol, centrifuged at 7 600 g for 
5 min at 4 °C, air-dried for 5 min, and resuspended in 20 µl of RNase-free water at 55 C for 5 
min.   
 
7.3.8 Reverse transcription PCR 
After reverse transcription with the QuantiTect Reverse Transcription Kit (Qiagen) according 
to the manufacturer's protocol, gene-specific qPCR assays were performed with a LightCycler 
480II using the following primers and universal probes (Roche, http://www.roche-applied-
science.com/sis/rtpcr/upl/ezhome.html):  
mICOS F1: CGGCAGTCAACACAAACAA;   R1: TCAGGGGAACTAGTCCATGC; probe: #6;  
hICOS F2:  GGATGCATACTTATTTGTTGGCTTA;  R2: TGTATTCACCGTTAGGGTCGT;  probe #47;  
Lsm1 F1:  TGGTCAGAGGAGAGAATGTGG;   R1: CTGAAGGGGCGTGTCACT; probe: #80.   
For relative quantification hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1) was 
used.   
Hprt1 F1: TCCTCCTCAGACCGCTTTT;   R1: CCTGGTTCATCATCGCTAATC;  probe: #95.   
All primer/probe sets were tested for efficiency and all results were analyzed by efficiency-
corrected advanced relative quantification.  For the quantification of miRNA expression 
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levels, miRNA species-specific first strand synthesis was carried out using the TaqMan 
microRNA Reverse Transcription kit and stem-loop primers specific for miR-101, miR-328, 
miR-196a and miR-214 (Applied Biosystems).  Quantitative PCRs for miRNAs were 
performed with a LightCycler 480II with U6 as a reference for relative quantification and 
analyzed by efficiency-corrected advanced relative quantification. 
 
7.4 Techniques for handling proteins 
7.4.1 Immunoprecipitation and analysis of associated RNAs 
For immunoprecipitation of protein-bound RNAs, 2x108 CD4 T cells or 1x107 transfected  
HEK293T cells were lyzed on ice in 2 ml IP-lysis-buffer (below).  Lysates were passaged 
through a 26G needle, shock frozen and cleared by centrifugation for 10 min at 10 000 g.  30 
µl Protein-G magnetic beads (Invitrogen) were coupled over night with 5 µg polyclonal anti-
Roquin or anti-GFP antibodies at 4°C.  Coupled beads were incubated with lysates (passed 
through a 0.45 µm filter) in the presence of 20 units RNasin at 4°C for 4 hours.  Prior to the 
isolation of RNA, the beads were washed twice with IP-lysis-buffer and twice with IP-wash-
buffer (below).  RNA was isolated from beads with the miRVana kit (section 7.3.7). 
 
IP-lysis-buffer: 
20 mM Tris-HCl pH 7.5 
150 mM NaCl 
0.25% NP-40 
1.5 mM MgCl2 
“complete” protease inhibitors without EDTA (Roche) 
1mM DTT 
 
IP-wash-buffer: 
20 mM Tris-HCl pH 7.5 
300 mM NaCl 
0.5% NP-40 
2.5 mM MgCl2 
“complete” protease inhibitors without EDTA (Roche) 
1 mM DTT 
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7.4.2 Luciferase assay 
For luciferase activity assays, MEF cells were plated onto 12-well plates at 1-2 x 105 cells per 
well and infected with adenoviruses.  After two days the dual-luciferase reporter assay 
(Promega) was performed.  PBS-washed cells were lyzed in 150 µl lysis-buffer (included in 
the kit) for 30 min at room temperature and subjected to one freeze and thaw cycle.  Lysates 
were cleared by centrifugation at 20 000 g for 5 min and 20 µl supernatant lights units were 
measured. 
 
7.4.3 Western blot analysis 
For Western blot analysis 5x106 cells were washed twice in PBS and then lyzed in 20 µl 
freshly prepared RIPA-buffer (below).  Lysates were incubated 15 min on ice and then 
centrifuged at 14 000 g and 4°C for 15 min.  Supernatants were transferred directly into a new 
tube containing 4x SDS sample buffer (below) and heated at 95°C for 5 min.    
 
RIPA stock solution:  
20 mM Tris-HCl, pH 7.5 
250 mM NaCl 
10 mM MgCl2  
1% NP-40 
0.1% SDS 
0.5% Na-desoxycholate 
 
RIPA-buffer (freshly added to RIPA stock solution):  
1 mM DDT  
1 mM PMSF  
10 µg/ml leupeptin  
10 µg/ml aprotinin  
8 mM beta-glycerophosphate  
0.1 mM sodium-orthovanadate  
10 mM NaF 
 
4x SDS sample buffer: 
200 mM Tris/HCl, pH 6.8 
8% SDS  
0.1% bromophenol blue 
4% glycerol 
10% fresh beta-mercaptoethanol 
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Thereafter, protein lysates were loaded on 8%, 9% or 10% Lämmli gels, depending on the 
protein size, run at 100 Volt and blotted on PVDF membranes at 40 V over night in blotting-
buffer (below).  Membranes were blocked in 5% milk dissolved in TBS (below) for two hours 
at room temperature.  A procedure of washing steps with TBS containing 0.05% Tween (3 
times 7 min) and incubation of primary antibody (for two hours) and secondary horseradish 
peroxidase-coupled (for 1 hour) antibodies followed.  Membranes were stained with ECL plus 
Western blotting reagent (GE healthcare). 
 
Blotting-buffer: 
15 g Tris 
72.1 g glycine 
1 l methanol 
ad 5 l H2O 
 
TBS: 
10 mM Tris/HCl pH 8.0 
150 mM NaCl 
 
Table 7-4 SDS-PAGE gels (for 2 gels): 
Ingredient Volume for 8% gel Volume 9% gel Volume for 10% gel 
Acrylamide 30% 2.7 ml 3 ml 3.3 ml 
1.5 M Tris/ HCl 2.5 ml 2.5 ml 2.5 ml 
10 % SDS 100 µl 0.1 ml 100 µl 
10% APS 100 µl 0.1 ml 100 µl 
H2O 4.6 ml 4.3 ml 4 ml 
TEMED 6 µl 6 µl 4 µl 
 
Table 7-5 Collecting gels: (for 2 gels): 
Ingredient Amount  
Acrylamide 30% 830 µl 
1.5 M Tris/ HCl 630 µl 
10 % SDS 50 µl 
10% APS 50 µl 
H20 3.4 ml 
TEMED 5 µl 
  
 
 
8.1 Evaluation of tools 
8.1.1 Determination of antibody specificity 
Antibodies against mouse Roquin and mouse MNAB were produced by immunizing rats with 
peptides from Roquin and MNAB proteins (section 6.1).  The peptides were chosen to obtain 
antibodies that would bind to both proteins by recognizing an amino-terminal epitope that is 
shared by Roquin and MNAB (antibody Q4-2).  In addition, peptides were selected to yield 
antibodies against carboxy-terminal epitopes that are unique in Roquin (antibody Q4-4) or 
MNAB (antibody POCO) proteins (Figure 8-1 a, page 54).  Peptide-antigen recognition was 
evaluated by enzyme-lined immunosorbent assay (ELISA) and protein identification using 
Western blots.  The hybridoma lines 5E9 (rat IgG2b), 6A6 (rat IgG2b), 5B11 (rat IgG2a), 2F6 
(rat IgG2a) and 3B5 (rat IgG2a) were repeatedly subcloned and specific Roquin and MNAB 
recognition of the monoclonal antibodies was verified by Western blotting of overexpressed 
proteins (Figure 8-1 b-e, page 54).  A549 cells were infected with recombinant adenoviruses 
generated from pCAGAdDu vectors that either encoded mouse Roquin or human MNAB 
using a multiplicity of infection (MOI) of 100.  Cells were lyzed in RIPA buffer and extracts 
from equal cell numbers were analyzed by SDS-PAGE.  Immunoblots were either probed 
with a mixture of the monoclonal antibodies Q4-2 6A6 and Q4-2 5E9 that recognized MNAB 
as well as Roquin (Figure 8-1 b, page 54).  In addition, a mixture of the monoclonal 
antibodies POCO 3B5 and POCO 2F6, which exclusively recognized MNAB (Figure 8-1 d, 
page 54), or with the monoclonal antibodies Q4-4 5B11, which specifically recognize Roquin 
(Figure 8-1 c, page 54), was tested.  The identity of the band that showed immunoreactivity 
with Roquin-recognizing antibodies was confirmed with commercial purified polyclonal 
antibodies (section 6.1), which exclusively recognize Roquin (Figure 8-1 e, page 54).  In 
summary, the overexpressed MNAB and Roquin proteins were equally well recognized by 
Q4-2 monoclonal antibodies and migrated at the calculated size of 132 kDa and 121 kDa, 
respectively.  As expected, MNAB was specifically detected by POCO antibodies.  Roquin 
was exclusively stained with Q4-4 monoclonal antibodies.  These results confirm the 
specificity of the generated monoclonal antibodies and demonstrate appropriate expression of 
8 Results 
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the full length Roquin and MNAB proteins from our adenoviral vectors.  Interestingly, 
cDNA-based MNAB expression not only resulted in the full-length protein, but also in a 
shortened version, which was detected by antibodies binding to either the carboxy-terminus or 
the amino-terminus.  Since POCO antibodies bind epitopes near the far end of the carboxy-
terminus, the second MNAB isoform is more likely to lack the amino-terminal region, 
presumably the RING finger domain (Figure 8-1 b, d, page 54).  The visualized difference 
between the two forms of MNAB indicates a difference of approximately 40 amino acids, 
further indicating that the second isoform might lack the RING finger domain.  This variant of 
the MNAB protein may derive from an alternative start codon usage or from proteolytic 
cleavage.  Although endogenous Roquin and MNAB protein levels can not be seen in these 
immunoblots, we could detect endogenous Roquin in different cell types and tissues with Q4-
4 and polyclonal antibodies, e.g, Figure 8-27 and other data not shown, but it remained a 
technical challenge to detect endogenous MNAB and was therefore analyzed via 
immunoprecipitation (Figure 8-11). 
8.1.2 Testing expression of Roquin and MNAB proteins 
Chimeras of mouse Roquin and human MNAB were generated through reciprocal exchange 
of their carboxy-  and amino-termini, using a conserved fusion site in the zinc finger of 
Roquin and MNAB (section 6.3).  To test whether these fusion proteins are correctly 
expressed and recognized by the corresponding antibodies, HEK293T cells were transfected 
using the calcium phosphate method (section 7.2.4) with retroviral expression vectors that 
encode wildtype Roquin or the Roquin/MNAB chimeras.  Equal cell numbers were lyzed in 
RIPA buffer and extracts from equal cell numbers were analyzed by SDS-PAGE.  Western 
blots were probed with a mixture of the monoclonal antibodies Q4-2 clone 6A6 and Q4-2 
clone 5E9 that recognized Roquin and both chimeras (Figure 8-2 b, page 55), or with a 
mixture of the monoclonal antibodies POCO clone 3B5 and POCO clone 2F6, which only 
recognized the chimera with the carboxy-terminus of MNAB (Roquin/MNAB) (Figure 8-2 c, 
page 55), or with the monoclonal antibody Q4-4 clone 5B11, which recognized Roquin and 
the chimera encoding the carboxy-terminus of Roquin (MNAB/Roquin) (Figure 8-2 a, page 
55).  The polyclonal antibodies (section 6.1) recognized Roquin and the MNAB/Roquin 
chimera (Figure 8-2 d, page 55).  Of note, the MNAB/Roquin chimera was also detectable in 
an amino-terminally shortened version showing a similar pattern as wildtype MNAB (Figure 
8-1 b, d, page 54).  This indicates that the alternative start codon or proteolytic cleavage is 
specified only through amino-terminal sequences of MNAB.  To verify that Roquin and its 
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mutant Roquin M199R are expressed at similar levels, A549 cells were infected with 
recombinant adenoviruses coding for either Roquin or Roquin M199R at a multiplicity of 
infection (MOI) of 100.  Extracts from equal cell numbers were analyzed by SDS-PAGE.  
Western blots were probed with specific antibodies for Roquin.  Immunoblot detection 
revealed comparable expression levels for both proteins (Figure 8-3, page 55).  To verify the 
expression of different deletion- and point-mutants of Roquin (section 6.3), HEK293T cells 
were transfected using the calcium phosphate method (section 7.2.4) with retroviral 
expression vectors encoding wildtype or deletion- and point-mutants of Roquin.  Equal cell 
numbers of transfected cells were analyzed by SDS-PAGE.  Western blots were either probed 
with a mixture of monoclonal antibodies Q4-2 clone 5E9 and clone 6A6, which recognizes an 
epitope within the ROQ domain, or with the polyclonal antibodies (Figure 8-1, page 54).  As 
expected, all deletion-mutants were recognized by the antibody mixture Q4-2, except for the 
one mutant lacking the RING finger and ROQ domain (Roquin aa 338-1130) (Figure 8-4 a, 
page 56).  All amino-terminal deletion- and point-mutants were recognized by the polyclonal 
antibodies (Figure 8-4 b, page 56).  The mutants lacking either the RING finger (Roquin aa 
55-1130) or the coiled-coil domain (Roquin aa 1-951) were expressed at lower levels as 
compared to wildtype Roquin or compared to the mutant lacking the carboxy-terminal 
regions, including the proline-rich region (Roquin aa 1-509) (Figure 8-4 a, page 56).  The 
latter was expressed at even higher levels than wildtype Roquin.  Importantly, point-mutants 
of Roquin (Roquin C14A/C34A, Roquin C419R/C428R) and the deletion-mutant lacking the 
RING finger and ROQ domain (Roquin aa 338-1130) were expressed similarly strong as 
wildtype protein (Figure 8-4 a, b, page 56). 
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Figure 8-1:  Analysis of mouse Roquin and human MNAB overexpression.  (a) Schematic depiction of the 
structure of mouse Roquin and MNAB with their individual RING and zinc fingers, ROQ and coiled-coil 
domains as well as proline-rich regions.  Black bars indicate the regions from which sequences were 
chosen to synthesize peptides and to generate rat monoclonal antibodies.  One additional black bar points 
to the region that includes epitopes recognized by commercial polyclonal antibodies.  (b-e) A549 cells were 
infected with recombinant adenoviruses to express either mouse Roquin or human MNAB.  Extracts 
derived from equal cell numbers were analyzed.  Immunoblots were probed with the antibodies indicated 
in (a), specifically recognizing mouse Roquin (c, e), mouse MNAB (d), or both proteins (b).  
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Figure 8-2: Expression test of Roquin/MNAB chimeras.  (a-d) HEK293T cells were transfected using the 
calcium phosphate method with retroviral constructs encoding wildtype mouse Roquin, human MNAB 
or chimeras of both proteins (section 6.3).  Western blots of overexpressed wildtype and chimeric 
proteins were probed with antibodies specifically recognizing Roquin (a, d), MNAB (c) or both proteins 
(b). 
 
Figure 8-3: Expression test of Roquin M199R compared to Roquin wildtype.  (a, b) A549 cells were 
infected with recombinant adenoviruses at an MOI of 100 generated from adenoviral pCAGAdDu vectors 
that encoded inserts of Roquin wildtype or the Roquin M199R mutant.  Cells were lyzed in RIPA buffer 
and extracts from equal cell numbers were analyzed by SDS-PAGE.  Immunoblots were probed with the 
indicated antibodies.   
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Figure 8-4: Expression test of deletion- and point-mutants of Roquin.  (a) Schematic depiction of domains  
and proline-rich regions within Roquin.  Numbers refer to amino acid end points of the generated deletion-
mutants.  (b, c) HEK293T cells were transfected using the calcium phosphate method with retroviral 
constructs encoding Roquin in its  wildtype form or as deletion- or point-mutants.  Cell lysates were 
separated by SDS-gels and immunoblots were probed with the indicated monoclonal (a) or polyclonal 
antibodies (b).   
 
8.1.3 Creating Dicer-deficient MEF clones 
Wildtype and Dicer fl/fl mouse embryonic fibroblasts (MEFs) were generated and 
immortalized through infection with a retrovirus that expressed SV40 large T as previously 
described [117].  Cells were then superinfected with a retrovirus to express Cre recombinase 
as well as a puromycin resistance gene and then treated with puromycin for five days.  
miRNA expression was decreased by ~90% ten days after infection, but regained wildtype 
levels after 26 days.  We suspected that cells in which the Cre recombinase did not effectively 
delete  Dicer alleles had a growth advantage over knockout cells and could therefore outgrow 
the latter (Figure 8-5 a, page 57).  Subsequently, clones were selected by limiting dilution.  
One Dicer fl/fl clone with deleted Dicer alleles and a Dicer wt clone were identified after Cre 
selection and kept in culture (Figure 8-5 b, page 57).  Even though Dicer knockout MEFs 
grew slower, they could be expanded in cell-culture and be infected with retroviruses and 
adenoviruses (section 8.2.7).   
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Figure 8-5: Cell growth of Dicer wildtype and knockout cells (a) and genomic PCR for Dicer alleles (b).             
(a) Dicer wildtype and knockout cells were compared in their cell growth.  (b) Genomic PCR was 
performed on bulk populations of wildtype and Dicer fl/fl mouse embryonic fibroblasts, as well as on 
individual clones after Cre infection.  Primers that can recognize the wildtype and floxed Dicer alleles 
(section 7.3.1) were used for genomic PCR. 
 
8.2 Analytical data 
8.2.1 Roquin is a repressor of translation 
A previous report suggested that Roquin regulates ICOS via the ICOS 3'UTR and that Roquin 
can promote ICOS mRNA decay [1].  Before we asked how Roquin regulates ICOS mRNA 
levels, we wanted repeated key experiments of that publication [1].  To do so a number of 
reporter constructs were generated.  First, a construct that only contains the ICOS coding 
region (ICOS CDS) or a construct containing the ICOS coding region and the 3'UTR (ICOS 
FL) (section 6.3) were generated and tested for repression by Roquin (Figure 8-6, page 58). 
Our experiments agree with the finding that Roquin can repress ICOS protein expression only 
when ICOS is expressed in the context of its 3'UTR (Figure 8-6 a, page 58).  This observed 
repression was lost upon removal of the carboxy-terminus of Roquin (aa 1-509), creating an 
inactive mutant of Roquin, which will be described in detail in section 8.2.3.  ICOS mRNA 
levels were lower in cells that overexpress ICOS FL and Roquin wildtype, compared to cells 
that overexpress ICOS FL and the inactive mutant, as determined by quantitative PCR (Figure 
8-6 b, page 58).  This confirms that Roquin can promote ICOS mRNA decay, as proposed 
earlier [1]. 
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Figure 8-6: Roquin represses ICOS mRNA through the 3'UTR.  MEF cells were transduced with 
retroviruses that encode either the ICOS coding sequence (ICOS CDS) or the ICOS coding sequence and 
the 3'UTR (ICOS FL).  They were superinfected with retroviruses encoding Roquin-WT or its inactive 
mutant (Roquin aa 1-509) (section 8.2.3) in the context of bicistronic Thy1.1 expression.  Flow cytometric 
analysis showing (a) contour plots of antibody-stained ICOS and Thy1.1 surface expression.  (b) ICOS 
mRNA levels were quantified from cells that were transduced with ICOS FL and Roquin or ICOS FL and 
Roquin 1-509, as shown in the upper panel of (a). 
 
Second, constructs were generated to test whether Roquin activity solely depends on the 
3'UTR, but is independent from the coding region.  For that, the coding regions of human 
CD4, another membrane protein that is translated at the endoplasmatic reticulum, or of GFP, 
an intracellular protein that is translated in the cytoplasm, were fused to the 3'UTR of ICOS.  
3T3 cells were retrovirally infected with either one of these constructs and superinfected with 
retroviruses encoding wildtype Roquin or the inactive mutant of Roquin (Figure 8-7, page 
59).  To compare Roquin-dependent downregulation of these proteins, human CD4 and GFP 
levels were quantified on cells with low, intermediate or high surface expression of Thy1.1.  
The Thy1.1 marker is translated by an IRES sequence and therefore co-expressed with either 
Roquin or its inactive mutant.   
Overexpression of wildtype Roquin effectively reduced the levels of human CD4 or GFP 
proteins and occurred in a dose-dependent manner, but was not observed for Roquin's inactive 
mutant (Figure 8-7, page 59).  However, Roquin-mediated repression was stronger in cells 
that were transduced with a construct that encoded the coding region of ICOS together with 
its 3'UTR (Figure 8-7, page 59). 
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Figure 8-7: Roquin-mediated repression of ICOS does not depend on sequences in the coding region of 
ICOS.  3T3 cells were transduced with retroviruses that encode the coding regions of either human CD4 
(a, b), GFP (c, d) or ICOS (e, f) upstream of the 3'UTR of ICOS.  Cells were superinfected with Roquin-
WT or its inactive mutant (Roquin aa 1-509) co-expressed with Thy1.1 from bicistronic retroviruses.  
Flow cytometric analysis (a, c, e) shows contour plots of CD4/GFP/ICOS and Thy1.1 expression.  The 
boxes indicate cells with low, intermediate and high Thy1.1 expression that were used for the 
quantification shown in (b, d, f) of mean fluorescence intensities of antibody-stained human CD4 or ICOS 
or the mean fluorescence intensity emitted from GFP. 
 
To unambiguously demonstrate Roquin's strong dependence on the ICOS 3'UTR for the 
downregulation of ICOS, a luciferase assay with an adenoviral luciferase reporter construct 
was performed (Figure 8-8, page 60).  This construct contained the renilla luciferase open 
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reading frame in conjunction with the 3’UTR of ICOS as well as an independently co-
expressed firefly luciferase open reading frame.   
 
Figure 8-8: Roquin represses the renilla luciferase open 
reading frame placed in the context of the ICOS 3'UTR.  
MEFs were co-transduced with GFP or Roquin IRES-
GFP and the ICOS 3'UTR luciferase reporter 
adenoviruses.  The ratio of measured renilla and firefly 
luciferase light units is shown.   
 
 
Co-infection of Roquin IRES-GFP or GFP with the ICOS 3'UTR reporter construct revealed 
that Roquin was able to repress the renilla luciferase open reading frame in the context of the 
ICOS 3'UTR (Figure 8-8).  Finally, a construct was generated to test whether Roquin 
represses ICOS in a cap-dependent manner.  This construct contained the ICOS coding region 
and its 3'UTR (ICOS full length) downstream of an IRES sequence.  Translational repression 
by Roquin was compared to a construct encoding the full length open reading frame of ICOS 
that was translated in a 5'CAP-dependent manner (Figure 8-9).   
 
Figure 8-9: Roquin decreases ICOS levels in a 5'CAP-independent manner.  3T3 cells were either 
transduced with retroviruses that encode an IRES sequence placed upstream of the ICOS coding region 
followed by the ICOS 3'UTR or transduced with a virus that translates ICOS and its 3'UTR 5'CAP-
dependent.  Additionally they were superinfected with Roquin-WT from a bicistronic Thy1.1 co-
expressing retrovirus.  Flow cytometric analysis shows contour plots of ICOS and Thy 1.1 expression (a).  
Boxes indicate cells with low, intermediate and high Thy1.1 expression used for quantification (b). 
 
To visualize a possible partial contribution of the 5'CAP to Roquin-dependent downregulation 
of ICOS, the levels of ICOS surface protein were quantified on cells with low, intermediate or 
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high surface expression of Thy1.1 in both experiments.  Roquin repressed ICOS levels in the 
context of an IRES sequence or with a 5'CAP structure without attenuation and in a similar 
dose response. 
 
In section 8.1.1 it was observed that the paralog of Roquin, MNAB, when expressed from a 
cDNA, resulted in a full length as well as in a truncated form that possibly lacks the RING 
finger domain.  This raised the question whether biologic activities of Roquin or MNAB 
depend on the RING finger.  Since there were no previous reports about MNAB targets, 
Roquin-mediated ICOS repression was determined for a Roquin mutant that was deleted in 
the RING finger or contained two point-mutations in the RING finger that are homologous to 
mutations in RING fingers that had been shown to inactivate other E3 ligases [118, 119] 
(Figure 8-10). 
 
 
Figure 8-10: The RING finger domain contributes, but is not essential, for Roquin activity.  Flow 
cytometric analysis showing MEF cells that were transduced with retroviruses encoding the human ICOS 
cDNA with 3’UTR and superinfected with Roquin or Roquin proteins with deletion- or point-mutantions 
in the RING finger from bicistronic Thy1.1 co-expressing retroviruses. 
 
Interestingly, point-mutations or deletion of the RING finger in Roquin only cause a moderate 
decrease in activity, compared to Roquin wildtype (Figure 8-10).  As compared to wildtype 
Roquin, the point-mutant was expressed at a similar level.  However, the RING finger 
deletion-mutant (Roquin aa 55-1130) was expressed at lower levels (Figure 8-4, page 56).  
This may explain why the point-mutation imposed a stronger repressive effect on ICOS than 
the deletion-mutant.  The results show that Roquin-mediated ICOS repression does not 
require the RING finger.  Therefore, Roquin appears to be different from other E3 ubiquitin 
ligases that completely depend on their intact E3 ligase activity [25, 120, 121].  Hence, the 
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data suggest that Roquin regulates ICOS on the mRNA level and that the RING finger 
domain only contributes to its full activity.  
8.2.2 MNAB, a paralog of Roquin, is unable to downregulate ICOS 
MNAB and Roquin are paralogs with a similar domain organization.  Both proteins have 
amino acid identities ranging from 71.4% within the RING finger, 92.4% in the newly 
defined ROQ domain and only 18.9% in the zinc finger domain.  However, this degree of 
similarity for the RING finger and ROQ domain indicates that both proteins could perform 
similar functions.   
To address this question we compared protein levels of mouse Roquin and mouse MNAB.  
Since Roquin protein levels in mouse tissue are highest in the thymus (data not shown), we 
compared Roquin and MNAB protein levels in this organ.  To be able to detect both proteins, 
an enrichment was performed by immunoprecipitation with an antibody (Q4-2) that 
recognizes an epitope from a peptide that is shared in both proteins.  Endogenous MNAB 
migrates higher than Roquin, as expected (section 8.1.1).  MNAB appears only in one band, 
whereas endogenous Roquin migrates in two isoforms.  Interestingly, MNAB was much 
higher expressed than Roquin (Figure 8-11 a).  Comparing mRNA expression levels of 
Roquin and MNAB in lymphoid organs, Roquin and MNAB mRNAs show a similar expression 
profile, with highest expression in the thymus, followed by slightly decreased expression in 
lymphnodes and a significant lower expression in spleen (Figure 8-11 b).  It is not clear how 
Roquin and MNAB levels relate to each other on mRNA levels since the measurements were 
performed in different PCR runs.  These cannot be compared reliably with each other due to 
technical variations.  Summarizing, Roquin and MNAB show a similar expression profile, but 
MNAB might be higher expressed in general, at least on the protein level.  It should be noted 
that the differential expression of MNAB and Roquin in thymus, lymhnodes and spleen can 
also be due to the different T and B cell-composition of these organs and that the data 
presented above probably reflect the differential expression of Roquin and MNAB mRNA in 
lymphocytic cells. 
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Figure 8-11: MNAB and Roquin protein and mRNA expression in lymphoid organs.  (a) 
Immunoprecipitations of Roquin and MNAB from thymus were performed with an antibody recognizing 
MNAB and Roquin (Q4-2) (section 8.1.1).  Extracts from equal cell numbers were used for 
immunoprecipitation and analysis by SDS-PAGE.  Immunoblots were probed with the indicated 
antibodies.  (b) Thymus, lymph nodes and spleen were isolated from BALB/c mice.  Single cell 
suspensions were used for RNA isolation.  Roquin and MNAB mRNA expression levels were determined 
by quantitative PCR.   
 
To investigate whether MNAB can also downregulate ICOS, ICOS surface levels of in vitro 
differentiated Th2 cells that overexpressed Roquin or its paralog MNAB were compared.  
Primary CD4 T cells from DO11.10 CAR∆1 mice (section 6.6) were used to introduce 
adenoviral expression vectors (section 6.3.2).  After in vitro differentiation of primary CD4 T 
cells into Th2 cells, the cells were infected with bicistronic adenoviruses that encode MNAB, 
Roquin or Roquin M199R and in each case GFP from an IRES sequence.  Cells 
overexpressing MNAB, and consequently also GFP, did not significantly decrease ICOS 
expression (Figure 8-12 a, c, page 64).  In the same approach Roquin effectively reduced 
ICOS surface levels (Figure 8-12 a).  Furthermore, the effect was exclusively observed in 
GFP positive cells, in cells that actually overexpressed Roquin.  The exchange of amino acid 
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199 from methionine to arginine created a functional hypomorph of Roquin that 
downregulated ICOS with an attenuated dose response, similar to previously reported findings 
[1, 2].  This effect of Roquin was specific for ICOS as there was no change in the surface 
expression of another activation-induced protein CD44 (Figure 8-12 b, d). 
 
 
Figure 8-12: Roquin has specialized to repress ICOS surface levels on T cells.  (a-d) In vitro differentiated 
Th2 cells from DO11.10 CAR∆1 mice were infected with the indicated adenoviral vectors at an MOI of 50 
on day 4 and analyzed two days later by flow cytometry for ICOS (a) or CD44 (b).  The boxes (a, b) 
indicate GFP positive cells, for which ICOS (c) or CD44 expression levels (d) were quantified. 
 
To identify unique sequences in Roquin that are critical for ICOS downregulation chimeras of 
Roquin and MNAB were analyzed for ICOS repression.  In these chimeras the conserved 
carboxy-termini of Roquin and MNAB were reciprocally exchanged (section 6.3).  
Expression of Roquin/MNAB chimeras in MEF cells revealed that sequences carboxy-
terminal to the zinc finger in Roquin contribute to downregulate the co-expressed ICOS 
(Figure 8-13, page 65). 
In fact, the amino-terminus of MNAB in the context of the carboxy-terminus of Roquin was 
able to support ICOS downregulation.  In contrast, the carboxy-terminus of MNAB fused to 
the amino-terminus of Roquin produced a protein with strongly reduced activity (Figure 8-13, 
page 65). 
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Figure 8-13: The carboxy-terminus of Roquin has specialized for efficient ICOS repression.  (a-b) MEF 
cells were transduced with retroviruses that encoded the human ICOS cDNA with 3’UTR and 
superinfected to co-express Roquin or MNAB or chimeras of both proteins from bicistronic Thy1.1 co-
expressing retroviruses.  Flow cytometric analysis showing contour plots of antibody-stained ICOS and 
Thy1.1 surface expression (a) or a bar diagram of the average ICOS expression from three independent 
experiments of the relative mean fluorescence intensity (MFI) of all cells normalized to the ICOS MFI in 
cells transduced with MNAB expressing constructs (b). 
 
These data show that the amino-terminal sequences of MNAB can exert a similar function as 
those of Roquin, whereas the carboxy-terminus cannot.  Retroviruses encoding both chimeras 
showed comparable mRNA expression as judged from Thy1.1 levels.  Transfection of the 
chimera-encoding vectors led to similar protein expression in HEK293 cells (Figure 8-2).  
However, quantification of ICOS downregulation revealed that even the amino-terminus of 
Roquin in the context of the carboxy-terminus of MNAB was more potent in repressing ICOS 
than the corresponding sequences in MNAB (Figure 8-13).  These findings demonstrate that, 
in contrast to MNAB, the entire Roquin protein, but especially its carboxy-terminus, has 
evolved for efficient downregulation of ICOS.   
 
8.2.3 The carboxy-terminus of Roquin determines the localization of Roquin to 
P bodies 
To investigate whether Roquin protein is enriched in a specific subcellular localization, 
confocal microscopy studies of HEK293T cells, transfected with Roquin proteins fused to an 
amino-terminal or carboxy-terminal GFP, were performed.  The images show that the green 
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fluorescent signal from wildtype Roquin co-localized with endogenous Rck (Figure 8-14 a), a 
marker of processing bodies (P bodies) [122].  
 
Figure 8-14: Roquin co-localizes with P body-markers.  (a-c) Confocal microscopy was performed to 
determine co-localization of endogenous Rck (stained with anti-Rck in red) with GFP tagged-Roquin 
(green) (a) as well as co-localization of Flag-HA tagged-Ago2 with GFP tagged-Roquin (green) in 
HEK293T cells (b) and localization pattern of GFP-tagged Roquin in T cells (c). 
 
We also observed co-localization with co-expressed Flag-HA tagged Ago2 protein (Figure 
8-14 b), which had been shown to be predominantly cytoplasmic, but also localize to P bodies 
[92].  GFP-fused Roquin proteins were additionally compared to untagged Roquin proteins 
and all revealed the same subcellular localization (data not shown). 
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These findings demonstrate a co-localization of transfected Roquin with different P body 
markers.  Interestingly, a comparable localization pattern was observed when GFP-Roquin 
was introduced into primary CD4 T cells (Figure 8-14 c). 
Since the amino-terminal domains of Roquin and MNAB can be functionally exchanged, we 
tested if MNAB and Roquin localize in the same loci.  Indeed, Roquin and MNAB partially 
co-localize in A549 cells (Figure 8-15), indicating that MNAB may also be enriched in P 
bodies. 
 
 
Figure 8-15: Roquin and MNAB co-localize.  Immunofluorescence in A549 cells infected with adenovirus 
encoding GFP-Roquin and antibody stained MNAB as indicated.   
 
Roquin has previously been described to co-localize with TIA-1 in stress granules [2].  The 
proposed localization was tested and confirmed after induction of stress by treatment with 
arsenite (Figure 8-16).  Arsenite treatment is well known to induce a stress response in cells. 
 
Figure 8-16: TIA-1 and Roquin co-localize after stress-induction by arsenite.  HEK293A cells were 
transfected with FuGene HD and vectors encoding Roquin and YFP-tagged TIA-1, treated with 0.5 mM 
arsenite for 1 hour and stained for Roquin with the monoclonal antibody Q4-4 (section 6.1). 
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However, this co-localization was not observed in cells that were not exposed to stress (data 
not shown).  To find out whether Roquin-mediated downregulation of ICOS acts through 
TIA-1-dependent induction of stress granules, Roquin function was tested in the absence of 
TIA-1.  MEF cells deficient for TIA-1 have been shown to be impaired in stress granule 
assembly as determined by TIAR, G3BP and eIF3 staining [123].  TIA-1-deficient and 
control MEF cells (Figure 8-17 a) were sequentially transduced with retroviruses encoding 
ICOS and Roquin expression constructs and tested for Roquin-mediated ICOS repression.  
The data show no effect of TIA-1 deficiency on Roquin-mediated ICOS repression (Figure 
8-17 b).   
 
Figure 8-17: Roquin activity is independent of a TIA-1-mediated stress response.  (a) Western Blot 
analysis of TIA-1 wildtype and knockout cells for TIA-1 and Tubulin protein levels.  (b) Wildtype and 
TIA-1 -/- mouse embryonic fibroblasts were retrovirally transduced with human ICOS coding sequence 
containing its 3'UTR.  Superinfection was subsequently performed using bicistronic retroviral vectors 
expressing Roquin aa 1-509 (inactive mutant) or Roquin-WT and Thy1.1 from an IRES sequence.  Flow 
cytometric analysis shows antibody-stained ICOS and Thy1.1 expression. 
 
These results suggest that, at least in the absence of cellular stress, Roquin-mediated ICOS 
repression does not depend on TIA-1 function, but rather involves localization of Roquin to    
P bodies.  To test which domain in the Roquin protein determines the localization to P bodies, 
amino- and carboxy-terminal deletion-mutants of Roquin were generated (Figure 6-2) and 
tested for localization (Figure 8-18, page 69).  The Roquin-specific punctate pattern in the 
cytoplasm was observed for all but one mutant.  Mutants lacking the carboxy-terminal coiled-
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coil domain (Roquin aa 1-951), the amino-terminal RING finger and ROQ domains (Roquin 
aa 55-1130 and Roquin aa 338-1130) or the RING finger, ROQ and zinc finger domains 
(Roquin aa 441-1130) all maintained the characteristic expression pattern of Roquin (Figure 
8-18).  Interestingly, the carboxy-terminal deletion-mutant Roquin aa 1-509 exhibited 
aberrant diffuse cytoplasmic as well as low-level nuclear localization (Figure 8-18).  These 
findings imply that the carboxy-terminal region of Roquin is sufficient to co-localize Roquin 
with P body-markers and may confer repressive activity towards ICOS. 
 
Figure 8-18: The carboxy-terminus of Roquin determines the characteristic localization pattern of 
Roquin.  The localization of the indicated GFP-tagged wildtype and mutant Roquin proteins in HEK293A 
cells is shown.  Explanatory notes: Roquin aa 55-1130 is lacking the RING finger domain, Roquin aa 338-
1130 is lacking the RING finger and ROQ domain, Roquin aa 441-1130 is lacking the RING finger, the 
ROQ and Zinc finger domain, Roquin aa 1-509 is lacking the carboxy-terminal regions, including the 
proline-rich region, Roquin aa 1-951 is lacking the coiled-coil domain. 
 
To confirm that localization to P bodies is essential for Roquin function, the carboxy-terminal 
deletion-mutants of Roquin were tested for their efficiency to downregulate ICOS (Figure 
8-19).  As expected, the Roquin aa 1-509 mutant is completely inactive (Figure 8-19).  
Importantly, this mutation (Roquin aa 1-509) did not lead to lower expression levels (Figure 
8-4, page 56) and therefore was used as a negative control in the experiments seen in Figure 
8-6, page 58, Figure 8-7, page 59, Figure 8-17, page 68, Figure 8-27, page 78, and Figure 
8-29, page 81.  The Roquin mutant lacking the coiled-coil domain (Roquin aa 1-951) has a 
slightly reduced activity (Figure 8-19, page 70).  This reduction could be intrinsic to the 
mutant protein, but may also be due to a weaker expression, which the Roquin aa 1-951 
mutant shows upon transfection in HEK293A cells (Figure 8-4, page 56).  Together, these 
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findings imply that the carboxy-terminal region of Roquin is essential for ICOS 
downregulation and sufficient to co-localize Roquin with P body markers.  
 
Figure 8-19: The carboxy-terminus is required for Roquin-mediated ICOS repression.  (a-b) MEF cells 
were sequentially transduced with retroviruses encoding ICOS and the indicated Roquin proteins that co-
expressed Thy1.1 from an IRES sequence.  Flow cytometric analysis showing antibody-stained surface 
expression of ICOS and Thy1.1 in contour plots (a) and a bar diagram of the average MFI of ICOS (from 
three independent experiments) normalized to ICOS levels in empty vector (IRES-Thy1.1)-transduced 
cells (b).  Explanatory notes: Roquin aa 1-509 is lacking the carboxy-terminal regions, including the 
proline-rich region, Roquin aa 1-951 is lacking the coiled-coil domain. 
 
8.2.4 Roquin requires the P body components Rck and Lsm1 for 
posttranscriptional gene silencing of ICOS  
To test whether Roquin-mediated repression of ICOS depends on P body function, an 
adenoviral knockdown against the two P body components Rck and Lsm1 (section 5.3.2) was 
established.  The knockdown of Roquin itself (shRc3h1) was used as a positive control.  One 
shRNA sequence out of four was identified to efficiently reduce Roquin or Rck target proteins 
or Lsm1 target mRNA, as determined by Western blot or quantitative PCR, respectively 
(Figure 8-20, page 71).  MEF cells were transduced with retroviruses that encoded ICOS and 
Roquin IRES-Thy1.1 and superinfected with adenoviruses that encoded shRNAs directed 
against Roquin, Rck or Lsm1.  Cells that were infected with an shRNA against Roquin 
(Rc3h1) strongly decreased the levels of the Thy1.1 marker protein that was co-expressed 
with Roquin from an IRES sequence (Figure 8-21 a, third plot from the left, page 72).  A 
similar strong decrease was observed for the Roquin protein itsel (Figure 8-20, page 71).  
Therefore, not only Roquin protein levels were visually affected, but also the marker protein 
that was co-expressed from the bicistronic mRNA.  At the same time ICOS surface 
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expression increased to levels that even exceeded the expression on cells that were not 
transduced with Roquin retroviruses (Figure 8-21 a, compare third and first contour plot from 
the left, page 72).  The data imply that ICOS levels are repressed by exogenous as well as 
endogenous Roquin.  This is consistent with detectable endogenous Roquin expression in 
MEF cells (Figure 8-27 c, page 78).  Although introduction of an shRNA directed against 
Lsm1 had only a moderate effect on Lsm1 mRNA levels (Figure 8-20 b, page 71), the 
knockdown led to partially increased ICOS levels in Roquin expressing cells (Figure 8-21 a, 
c, page 72).  Importantly, a knockdown of Rck very effectively increased ICOS levels in 
Roquin expressing cells (Figure 8-21 b, d, page 72).  These levels increased to even higher 
levels than in cells that were not Roquin transduced, similar to the effect observed upon 
Roquin knockdown.  However, in this case the increase of ICOS occurred in the absence of 
changes in Thy1.1 expression.  This finding indicates that the knockdown of Rck neutralized 
the function of endogenous as well as exogenous Roquin proteins without affecting 
expression of the mRNA encoding Roquin and IRES-Thy1.1 (Figure 8-21 b, page 72). 
 
Figure 8-20:  Evaluation of adenoviral knockdown of Roquin, Lsm1 and Rck.  Protein or RNA extracts 
from cells expressing adenoviral shRNA hairpin constructs against Rc3h1, Lsm1 or Rck were evaluated by 
Western blots against Roquin (a) and Rck (c) or by quantitative PCR for Lsm1 (b).  Please note that the 
cells used in (a, b) correspond to the transduced MEF cells shown in Figure 8-21, whereas Rck knockdown 
(c) was evaluated in A549 cells. 
Results   72 
 
Figure 8-21: Knockdown of Roquin, Lsm1 or Rck increases ICOS expression.  (a-d) MEF cells were 
sequentially transduced with retroviruses to co-express ICOS and Roquin and were superinfected with 
adenoviruses encoding shRNAs against the indicated target mRNAs.  Flow cytometric analysis shows 
ICOS and Thy1.1 levels in contour plots (a, b) or relative ICOS expression in histograms (c, d) three days 
after superinfection. 
 
In summary, the data presented in this chapter demonstrate that Roquin-mediated ICOS 
repression on the one hand requires carboxy-terminal sequences that translocate Roquin to P 
bodies (section 8.2.3).  On the other hand repression strongly depends on functional 
interaction with the P body components Rck and Lsm1. 
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8.2.5 The amino-terminus of Roquin binds to ICOS mRNA 
A possible mechanism by which Roquin could posttranscriptionally repress ICOS mRNA 
would be binding of Roquin to ICOS mRNA and its translocation into P bodies.  To test this 
hypothesis, an interaction of Roquin with ICOS mRNA was tested in two different 
approaches.  First, RNA-IPs were performed under highly stringent conditions and with 
protein extracts prepared after crosslinking of intact cells with formaldehyde treatment and 
subsequent sonification (section 7.3.6).  For that, HEK293 cells were transfected with 
constructs expressing GFP-Roquin and ICOS mRNA containing its 3'UTR.  Subsequently, 
RNA-IPs were performed using anti-GFP antibodies.  PCR reactions with specific primers for 
ICOS were performed on reversely transcribed RNA prepared from immunoprecipitates.  The 
results revealed that ICOS mRNA was strongly bound by Roquin (Figure 8-22 upper panel, 
lane 1).  This interaction was increased over background levels of ICOS mRNA as judged by 
a negative control measuring unspecific ICOS mRNA-GFP protein interactions (Figure 8-22, 
upper panel, compare lanes 2 and 1).  As an additional negative control, the abundantly 
expressed 5S rRNA from the RNA-IPs was PCR-amplified as described above.  No 
unspecific interaction of Roquin-GFP and 5S rRNA was detected (Figure 8-22, lower panel, 
lanes 1 and 2).  This further indicated that the detected interaction between Roquin-GFP and 
ICOS mRNA was specific. 
Figure 8-22:  Roquin interacts with ICOS mRNA.  
RNA-IPs were performed with anti-GFP 
antibodies on extracts from crosslinked and 
sonicated HEK293T cells that were co-transfected 
with expression vectors for ICOS and GFP tagged-
Roquin or GFP alone.  RNA in the precipitates 
were reversly transcribed and PCR-amplified 
with primers specific for the 3’UTR of human 
ICOS or primers specific for 5S rRNA and 
analyzed on ethidium bromide stained agarose 
gels. 
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In a second approach we wanted to test whether endogenous Roquin interacts with 
endogenous ICOS mRNA.  Extracts were prepared from primary Th1 cells and 
immunoprecipitations or mock precipitations, this time without crosslinking, were performed 
with antibodies against Roquin.  Roquin protein was found to be efficiently enriched after 
immunoprecipitation (Figure 8-23 a).  In parallel immunoprecipitation experiments, the 
associated RNA was extracted and ICOS mRNA amounts were determined after reverse 
transcription and quantitative PCR.  The physical association of endogenous Roquin with 
endogenous ICOS mRNA in T cells was confirmed in three independent experiments (Figure 
8-23 b). 
 
Figure 8-23: Roquin binds to endogenous ICOS mRNA in T cells.  (a-b) Co-immunoprecipitation of 
endogenous ICOS mRNA with endogenous Roquin protein from Th1 cell protein extracts applying anti-
Roquin antibodies.  (a) Immunoprecipitated Roquin protein was detected by Western blot.  (b) The 
average co-immunoprecipitated endogenous mouse ICOS mRNA was determined by quantitative PCR 
and was normalized to input levels from three independent experiments.  Statistical significance was 
determined by Student's T-test with a p value of 0.02. 
 
To analyze the involvement of individual Roquin domains in ICOS mRNA binding, GFP-
fused deletion-mutants of Roquin were co-transfected with an human ICOS expression 
construct into HEK293T cells (Figure 8-24 a, page 75).  Clearly, the interaction between 
Roquin and ICOS mRNA did not depend on the carboxy- but rather on the amino-terminus of 
Roquin.  In fact, the interaction of Roquin and ICOS mRNA was even increased for the 
inactive deletion-mutant Roquin aa 1-509, compared to Roquin wildtype (Figure 8-24 a, page 
75).  However, this effect was most likely due to increased efficiency of immunoprecipitation 
for this mutant, compared to the other Roquin mutants (data not shown).  The fact that this 
mutant cannot localize to P bodies (section 8.2.3) indicates that the detected RNA-interactions 
result rather from interactions in the cytoplasm than from interactions in P bodies.  Deletion 
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of the amino-terminal RING finger alone (Roquin aa 55-1130) had a small negative effect on 
ICOS mRNA interaction (Figure 8-24).  However, ICOS mRNA interaction was completely 
abolished for the mutant lacking the RING finger and ROQ domain (Roquin aa 338-1130) or 
the mutant lacking the RING finger, ROQ and zinc finger domain (Roquin aa 441-1130) 
(Figure 8-24). 
 
Figure 8-24: The amino-terminal ROQ domain is critical 
for RNA-binding.  RNA immuno-precipitation with anti-
GFP antibodies using protein extracts from HEK293T cells 
that were co-transfected with GFP tagged- wildtype or 
deletion-mutants of Roquin together with ICOS.  The bar 
diagram displays the fraction of co-immunoprecipitated 
ICOS mRNA compared to input levels.  Explanatory notes: 
Roquin aa 1-509 is lacking the carboxy-terminal region 
including the proline-rich region, Roquin aa 55-1130 is 
lacking the RING finger domain, Roquin aa 338-1130 is 
lacking the RING finger and ROQ domain, Roquin aa 441-
1130 is lacking the RING finger, the ROQ and Zinc finger 
domain. 
 
To investigate if RNA-binding is essential for Roquin repressive activity, the amino-terminal 
mutants were analyzed for their capacity to downregulate ICOS.  MEF cells were sequentially 
transduced with retroviral vectors coding for ICOS and Roquin wildtype or mutants.  In these 
experiments Roquin-mediated repression of ICOS was abolished for the mutant lacking the 
ROQ domain (Roquin aa 338-1130) and also for the mutant lacking the ROQ and zinc finger 
domain (Roquin aa 441-1130) (Figure 8-25, page 76).  This result clearly shows that RNA-
binding by the ROQ domain is essential for Roquin activity.  To investigate a possible 
involvement of the CCCH-type zinc finger, two conserved cysteines C419 and C428 were 
replaced with arginines.  Individual mutations of conserved cysteines in TTP have been 
demonstrated to interfere with RNA binding [70].  Combined mutations of the first and 
second cysteines in the zinc finger of Roquin did not decrease ICOS expression of this mutant 
(Figure 8-25, page 76), but revealed a moderate negative effect on its activity.  This was most 
apparent in cells with high levels of Thy1.1 expression (Figure 8-25, page 76).  These 
findings suggest that zinc finger and RING finger (section 8.2.1) domain may cooperate 
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physically or functionally with the ROQ domain.  However, only the ROQ domain is essential 
for binding to ICOS mRNA.   
 
Figure 8-25: The ROQ domain is essential for Roquin-mediated ICOS repression.  (a-b) MEF cells were 
sequentially transduced with ICOS and the indicated wildtype or mutant Roquin encoding retroviral 
vectors.  Flow cytometric analysis showing  antibody-stained ICOS and Thy1.1 surface expression levels in 
contour plots (a) or the average ICOS MFI, from three independent experiments, normalized to control 
transduced cells (b).  Explanatory notes: Roquin C419R/C428R is mutated at two conserved cysteines 
within the Zinc finger domain, Roquin aa 338-1130 is lacking the RING finger and ROQ domain, Roquin 
aa 441-1130 is lacking the RING finger, the ROQ and Zinc finger domain. 
 
In summary, it was demonstrated that the amino-terminus and carboxy-terminus of Roquin 
provide essential functions for efficient posttranscriptional ICOS repression by binding to 
ICOS mRNA and by localization to P bodies, respectively. 
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8.2.6 Roquin activity is Argonaute independent 
P bodies are not only enriched in enzymes of the general mRNA decay machinery but also in 
components of the miRNA-pathway, e.g. Argonaute proteins (section 5.3.1).  Argonaute 
proteins bind to microRNAs and represent the core enzyme of the miRISC.  No inhibitory 
miRNA effect can be imposed on mRNAs without Argonaute (Ago) proteins or miRISC 
formation.  The miRISC requires, similar to Roquin, the P body components Rck and, in 
some cases, also Lsm1 (section 5.3.1) for translational repression (section 8.2.4).  It was 
previously suggested that Roquin-dependent ICOS repression is mediated by miRNAs [1].  
How Roquin cooperates with the miRNA pathway was not clarified.  Therefore, we tested 
contribution of miRISC components for Roquin-mediated ICOS repression.  Among the 
mammalian Argonaute 1-4 family members Ago2 is unique, because it is the only Ago 
protein with endonucleolytic activity [124].  We obtained Ago2 knockout MEF cells to 
analyze Roquin-mediated ICOS repression in the absence of Ago2.  First, it was tested 
whether reconstitution with human Flag-tagged Ago2 (hAgo2) restored shRNA-dependent 
knockdown of target mRNAs.  In this process Ago2 cleaves mRNAs that contain perfectly 
matching sequences complementary to the sh/siRNA used.  After retroviral introduction of 
human Flag-tagged Ago2, the cells re-acquired the ability to efficiently support shRNA 
dependent knockdown of ectopically expressed mouse CD4.  The same shRNA against CD4 
had no effect on CD4 expression in Ago2-deficient cells (Figure 8-26).   
 
Figure 8-26: Ago2-/- MEFs can re-establish 
siRISC activity after Ago2 overexpression.  
Ago2 -/- MEF cells were sequentially 
transduced with mouse CD4 or control 
retroviruses and superinfected with 
retroviruses encoding an shRNA against 
mCD4 or superinfected with the shRNA in 
combination with Flag-HA tagged-Ago2.  Cells 
were analyzed by flow cytometry to show an 
overlay histogram of relative CD4 expression 
in the transduced cells. 
 
Roquin activity was determined in Ago2 knockout MEF cells or knockout cells, in which 
human Flag-tagged Ago2 was re-expressed.  The absence of Ago2 did not compromise 
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Roquin-dependent downregulation of ICOS.  ICOS levels strongly decreased upon co-
expression of Roquin wildtype (Figure 8-27 a, upper panel, right contour plot, page 78) as 
compared to expression of the inactive mutant of Roquin (Figure 8-27 a, upper panel, left 
contour plot).  Surprisingly, re-expression of functional human Ago2 strongly interfered with 
Roquin-dependent downregulation of ICOS (Figure 8-27 a, lower panel, right contour plot).   
 
 
Figure 8-27: Ago2 overexpression interferes with Roquin activity.  (a-b) Ago2-/- MEF cells were 
transduced with retroviruses to co-express ICOS together with wildtype or mutant Roquin from IRES-
Thy1.1 vectors alone or in combination with human Flag-tagged Ago2.  (a) Flow cytometric analysis 
showing ICOS and Thy1.1.  (b) Western blot analysis for Flag-tagged Ago2 levels based on the cells shown 
in (a).  (c) Western blots of MEF cells, which were retrovirally transduced, as indicated, to overexpress 
Flag-tagged Ago2 and Roquin and were analyzed for Ago2, Roquin and Tubulin expression.   
 
To rule out that Ago2 overexpression affected Roquin expression, both proteins were 
analyzed in retrovirally co-transduced MEF cells (Figure 8-27 c).  Ago2 overexpression did 
not change Roquin protein levels (Figure 8-27 c).  These findings accentuate that Roquin-
dependent silencing of ICOS does not require the endonucleolytic activity of Ago2, but 
operates in a closely connected pathway, which is inhibited by experimentally increased Ago2 
expression levels.  Ago2 functionally overlaps with Ago1, 3 and 4 in miRNA-dependent 
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translational inhibition.  Therefore Roquin-induced downregulation of ICOS was tested in 
embryonic stem (ES) cells containing homozygous deletions of Ago1, 3 and 4 genes (ES cell 
line B9) [125].  In addition, the ES cell line E7, which is deficient for endogenous mouse 
Ago1-4 gene products, was analyzed.  Since complete absence of all Ago proteins results in 
apoptosis, these cells can only be expanded in culture as they express low levels of a human 
Ago2 transgene from a loxP-flanked locus.  In these cells human Ago2 can be deleted by 
activation of an estrogen receptor fused Cre recombinase, induced by tamoxifen (4'OH-T) 
treatment.  After tamoxifen treatment these cells are completely devoid of Ago1-4 gene 
products, but remain viable for up to 4 days before they start to undergo apoptosis [125].  Co-
infection of Roquin IRES-GFP or GFP with a ICOS 3'UTR luciferase reporter construct 
(section 6.3) revealed that Roquin was still able to repress the ICOS 3'UTR in cells without 
mouse Ago1, 3 and 4 (ES cell line B9) and in cells that lack mouse Ago1-4 but contain low 
amounts of hAgo2 (ES cell line E7).   
Importantly, E7 cells after 4'OH-T treatment showed an arrest in cell growth but were not 
impaired for Roquin-dependent ICOS repression (Figure 8-28 a, page 80).  The same results 
were obtained in these cells when Roquin activity on ICOS levels was analyzed by flow 
cytometry (Figure 8-28 b, page 80).  Measuring surface ICOS levels in cells that co-express 
GFP or Roquin IRES-GFP, a 4 to 10-fold repression of ICOS levels by FACS was detected 
(Figure 8-28 b, page 80) compared to a 6 to 9-fold repression of the ICOS reporter detected in 
luciferase assays (Figure 8-28 c, page 80).  Independent of the way of assessment, Roquin-
mediated ICOS repression was comparable strong in Ago knockout ES cells as observed in 
wildtype MEF cells and did not decrease after Tamoxifen treatment of E7 cells.   
These experiments demonstrate that Roquin-mediated ICOS repression does not require the 
presence of Ago1-4 proteins and is likely independent of miRNAs.  However, the role of 
miRNAs for Roquin activity will be addressed in detail in the following chapter. 
Results   80 
 
Figure 8-28: Ago 1, 2, 3 and 4 proteins are not required for Roquin-mediated ICOS repression.  The ES 
cell lines B9 and E7, or E7 treated with 4-hydroxy-tamoxifen (4’OH-T), were infected with adenoviruses 
that allow expression of GFP or Roquin IRES-GFP and were simultaneously co-infected with a second 
adenovirus that enables independent expression of renilla and firefly luciferases.  The renilla luciferase 
open reading frame was fused to the 3'UTR of ICOS.  (a) The average ratio from three independent 
experiments of renilla and firefly luciferase light units is shown.  (b) Flow cytometric analysis showing 
ICOS and GFP levels of the indicated ES cell lines that were co-transduced with ICOS and Roquin-IRES-
GFP or GFP encoding retroviruses. 
 
8.2.7 Roquin activity does not require miRNAs 
Although miRNA function in the absence of Ago1-4 proteins has not been reported, a second 
genetic approach was carried out to rule out a requirement for miRNAs in Roquin-mediated 
ICOS repression.  To obtain cells deficient in RNAi, Dicer-deficient MEF clones were 
generated (section 8.1.3).  Wildtype and Dicer-deficient cells were subsequently transduced 
with ICOS and Roquin, or with its inactive mutant (Roquin aa 1-509).  Of note, expression 
tests for several miRNAs by quantitative PCR revealed that miRNA levels were undetectable 
or more than hundredfold reduced in Dicer-deficient MEFs (Figure 8-29 a, page 81).  A 
fraction of the same cells that were used for miRNA quantification was analyzed by flow 
cytometry.  Roquin efficiently downregulated ICOS protein in wildtype, as well as in Dicer-
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deficient cells, compared to the inactive Roquin mutant (Figure 8-29 b).  To determine a 
possible partial contribution of miRNAs to Roquin-dependent downregulation of ICOS, ICOS 
levels were quantified in cells with low, intermediate or high surface expression of Thy1.1, 
the marker that was co-expressed with Roquin proteins from an IRES.  Roquin repressed 
ICOS levels in Dicer wildtype and knockout cells without attenuation and in a similar dose 
response (Figure 8-29 c).  It was previously reported that Roquin expression not only affects 
ICOS protein, but also mRNA levels [1].  The experiments presented here clearly demonstrate 
that Roquin induced a similar decay of ICOS mRNA in wildtype and Dicer-deficient cells 
(Figure 8-29 d).  
 
Figure 8-29: Roquin activity remains unaltered in the absence of miRNAs.  (a-d) Dicer-/- and wildtype 
MEF clones were sequentially transduced with retroviruses to co-express ICOS and the indicated Roquin 
proteins.  (a) Quantification of miRNA levels in Dicer-/- MEF cells normalized to wildtype levels.  (b) 
Flow cytometric analysis of antibody-stained Thy1.1 and ICOS surface levels in wildtype and Dicer-/- 
MEF cells.  (c) The average ICOS MFI is shown for middle and high Thy1.1 expressing cells, normalized 
to low Thy1.1 expressing cells, from three independent experiments.  (D) Quantification of ICOS mRNA 
levels.  All results shown in this figure are based on the same wildtype and Dicer-/- MEF cells. 
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To ensure that the generated Dicer-deficient cells are impaired in miRISC function the 
translational repression by miR-196a of the Hoxc8 3'UTR, a well-established target of this 
miRNA [126], was measured by using a dual luciferase assay.  The Hoxc8 3'UTR was 
strongly repressed by co-expression of a construct encoding pre-miR-196a in wildtype, but 
not in Dicer-deficient cells.  However, the same cells were still able to support Roquin-
mediated repression through the 3’UTR of ICOS as determined by dual luciferase 
measurement (Figure 8-30).    
 
 
 
Figure 8-30: Dicer deficient cells are 
impaired in miRNA function.  Wildtype and 
Dicer-/- MEF cells were co-transduced with 
GFP or miR-196 IRES-GFP and Hoxc8 
3'UTR luciferase reporter adenoviruses or 
with GFP or Roquin IRES-GFP and ICOS 
3'UTR luciferase reporter adenoviruses.  
The ratio of measured renilla and luciferase 
light units is shown.   
 
 
 
Together, these data completely rule out a requirement for miRNAs in Roquin-mediated 
ICOS repression as suggested earlier.  However, similar to the recent publication [1], a region 
in the 3'UTR of ICOS mRNA that contains the possible miR-101 recognition motif was found 
to contribute to Roquin-dependent ICOS repression (Figure 8-31).  In fact, Roquin-mediated 
repression was substantially impaired, when ICOS was expressed from a construct that 
contained a 3'-truncated 3'UTR (ICOS bp 1-2211), which lacked the putative miR-101 
binding site (Figure 8-31).  Nevertheless, this truncated 3'UTR still responded to a significant 
extent to Roquin-induced ICOS repression (Figure 8-31), indicating a more complex 
regulation. 
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Figure 8-31: A region in the 3'UTR of ICOS mRNA, containing the putative miR-101 binding site, is 
important for translational repression by Roquin.  (a-c) NIH3T3 cells were transduced with retroviruses 
encoding the full length ICOS or partial ICOS (bp 1-2211) cDNAs as depicted in (a) and superinfected 
with Roquin IRES-Thy1.1 retroviruses.  (b) Flow cytometric analyses showing ICOS and Thy1.1 levels.  
(c) The average ICOS MFI is shown for middle and high Thy1.1 expressing cells, normalized to low 
Thy1.1 expressing cells, from three independent experiments. 
 
8.2.8 Induced miRISC formation inhibits Roquin activity 
To test whether expression of Ago2 inhibits Roquin activity due to increased Ago2 protein 
levels or due to an increase in miRISC formation, the previously observed effect of Ago2 
overexpression was tested in wildtype and Dicer knockout cells.  Overexpression of Ago2 can 
only induce increased miRISC formation in Dicer wildtype cells.  Retroviral transduction led 
to a dramatic overexpression of Ago2, which was comparable in wildtype and Dicer-deficient 
cells (Figure 8-32 a, page 84).  Furthermore it slightly changed the cellular levels of several 
mature miRNAs in wildtype, but not in Dicer knockout cells (Figure 8-32 c, page 84).  
Importantly, overexpression of Ago2 only counteracted Roquin-induced ICOS repression in 
wildtype (Figure 8-32 b, upper panel, compare left and right contour plots, page 84), but not 
in Dicer-deficient cells (Figure 8-32 b, lower panel, compare left and right contour plot, page 
84).   
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Figure 8-32:  Induced miRISC formation interferes with Roquin activity.  Wildtype and Dicer-/- MEF 
cells were sequentially transduced with ICOS and Roquin together with Flaf-HA tagged Ago2.  Cells were 
analyzed for Ago2 levels by Western blot (a), for miRNA levels by RT-PCR (c) or for Roquin-mediated 
ICOS repression by measuring antibody-stained ICOS and Thy1.1 surface expression by flow cytometry 
(b). 
 
Subsequently, two conserved phenylalanines of Ago2 were mutated, which have been 
reported to be essential for the interaction with GW182 (section 5.3.3) as well as for miRNA 
loading [104].  These phenylalanines were changed to valines (F470V/F505V).  In contrast to 
wildtype Ago2, the F470V/F505V Ago2 mutant was unable to de-repress Roquin-mediated 
ICOS repression (Figure 8-33, page 85).  The findings demonstrate that Ago2 interferes with 
Roquin's function, but only in the context of intact miRNA biogenesis pathway and when 
miRNAs can be loaded onto RISC complexes.  Only when miRNAs are bound by the RISC 
complex, a functional interaction of Ago2 and GW182 occurs, which is essential for 
translational inhibition by miRNAs [127]. 
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Figure 8-33: Inhibiting of GW182 function interferes with Roquin activity.  Ago2-/- MEF cells were 
sequentially transduced with ICOS and Roquin encoding retroviruses and superinfected with wildtype or 
mutant Ago2 (F470V/F505V) or dominant-negative (DN) GW182 (1-498).  Flow cytometry was used to 
analyze ICOS and Thy1.1 expression (a) or to compare relative ICOS levels (b). 
 
The amino-terminus of GW182 has been shown to bind to Argonaute proteins and a carboxy-
terminal truncated GW182 can function as a dominant-negative protein for the siRNA and 
miRNA pathway, as well as for P body formation [102, 128, 129].  Interestingly, 
overexpression of the dominant-negative GW182 protein (1-498) also interfered strongly with 
Roquin's activity and resulted in even higher ICOS levels than observed in cells in which 
Roquin activity was blocked by Ago2 overexpression (Figure 8-33).  These results indicate 
that inhibition of GW182 function not only interferes with Argonaute and miRISC function, 
but also impairs Roquin-mediated ICOS repression.  Interestingly an interaction of Roquin 
with Ago2 was observed (Figure 8-34, page 86).  For that, HEK293T cells were transfected 
with constructs encoding GFP-tagged Roquin and Flag-tagged Ago2.  Immunoprecipitations 
for GFP were afterwards treated with RNase A (section 7.4.1).  Flag-tagged Ago2 co-
immunoprecipitated with GFP-Roquin efficiently and in a manner that was insensitive to 
RNase treatment, suggesting a direct protein-protein interaction.  It is tempting to speculate 
that the observed inhibition of Roquin activity by Ago2 overexpression is due to an 
interaction of the miRISC with Roquin, involving a possible mutual negative regulation. 
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Figure 8-34: Ago2 and Roquin interact in an RNA-independent manner.  HEK293T cells were transfected 
using the calcium phosphate method with constructs encoding GFP-tagged Roquin and human Flag-
tagged Ago2 as indicated.  Cells were lyzed and 5% of the cell lysates were loaded as input controls.  Anti-
GFP- immunoprecipitations were performed as described in section 7.4.1, treated with RNase A as 
indicated, washed and eluted from beads by boiling in SDS loading buffer.   
 
8.2.9 Summarizing results: Parallel pathways of Roquin- or miRNA-mediated 
posttranscriptional gene silencing 
The data presented are consistent with the following model: Roquin and miRISC 
posttranscriptional gene silencing are two parallel pathways that share downstream factors. 
miRNAs are bound by Argonaute proteins, which are part of the miRISC complex.  The 
loaded RISC complex can then bind to the target mRNA by complementary binding of the 
miRNA to recognition motifs within the 3'UTR of the target mRNA (section 5.3.3).  
Translocation of the target mRNA into P bodies can occur, but is not required for inhibition of 
translation.  Nevertheless, P body components, such as GW182 and Rck, are necessary for 
translational inhibition by miRNAs.  Lsm1, for example, is required for translation repression 
of approximately 5% of miRNA-targets (section 5.3.3).   
The amino-terminus of Roquin is required for RNA binding and can be functionally replaced 
by conserved sequences from Roquin’s paralog MNAB (section 8.2.2).  The carboxy-
terminus mediates P body localization and has specialized in Roquin for efficient repression 
of ICOS (section 8.2.3).  Roquin does neither require miRNAs nor Argonaute proteins for 
translational inhibition of ICOS (sections 8.2.6 and 8.2.7) but depends on the P body 
components Rck, GW182 and Lsm1 (section 8.2.4 and 8.2.8).  Enhanced miRISC function 
thereby may inhibit Roquin activity (section 8.2.8) through competition of Roquin and the 
miRISC for common factors like Rck, GW182 and Lsm1 (section 8.2.4), possibly by direct 
inhibition and interaction with Argonaute 2. 
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Figure 8-35 : Schematic representation of translation repression by (1) miRNAs and by (2) Roquin.  (1) 
miRNAs and proteins of the miRNA pathway are specialized trans-acting factors (section 5.3.1).  
Argonaute proteins can bind with the help of miRNAs to mRNAs, which causes translational repression 
and mRNA instability.  P body components, such as Lsm1, Rck and GW182, have been demonstrated to 
play a role in miRNA-dependent translational repression.  (2) Roquin can also bind to mRNA via its 
amino-terminal ROQ domain.  The carboxy-terminal regions within Roquin specify its localization to P 
bodies.  Certain P body components, such as Rck, GW182 and Lsm1 are required for full activity of 
Roquin.  Roquin-mediated repression does not require miRNAs and Argonaute proteins, but is inhibited 
through experimentally induced miRISC formation. 
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9.1 Molecular mechanism of Roquin-mediated ICOS repression 
This thesis demonstrates the molecular mechanism of Roquin-mediated ICOS repression and 
reveals Roquin as a trans-acting factor for ICOS expression.  The key experiments and results 
that are presented in here and lead to this model, will be discussed in this section.  Some 
important follow-up experiments will be proposed. 
 
9.1.1 Roquin binds to ICOS mRNA 
Testing the hypothesis that Roquin could bind ICOS mRNA, we find that mRNA binding is 
actually one critical part of the molecular mechanism by which Roquin represses ICOS.  The 
fact that Roquin protein and ICOS mRNA can be crosslinked in intact cells suggests that 
Roquin is in direct physical contact with RNA (Figure 8-22).  Additionally, endogenous 
mouse ICOS mRNA can be detected in immunoprecipitations of endogenous Roquin from T 
cell extracts (Figure 8-23).  Binding to RNA has been described for CCCH-type zinc finger 
proteins, such as TTP and Zc3h12a (section 5.3.1).  However, this thesis demonstrates that 
Roquin binds primarily via its ROQ domain to ICOS mRNA (Figure 8-24).  This conclusion 
arose from our GFP-immunoprecipitations with GFP-tagged deletion-mutants of Roquin, 
which produced reliable results.  It remained a technical challenge to estimate the exact 
contribution of the other amino-terminal domains to RNA binding, because point-mutated 
Roquin constructs were cloned without a GFP-tag, and immunoprecipitations with an 
antibody against Roquin were weaker and therefore more variable.  Nevertheless, we propose 
that Roquin binds to RNA through a protein surface that is composed of the ROQ domain and 
additional domains such as the zinc finger or even RING finger, because point-mutations in 
these domains impaired ICOS repression (Figure 8-10 and Figure 8-25).  Such a novel mode 
of interaction with RNA is supported by an earlier report showing that individual mutation of 
two cysteines in the zinc finger of the paralog MNAB did not abolish, but rather reduced 
binding of MNAB to DNA [114].  Further support for a composite interaction of the ROQ 
and zinc finger domains with RNA comes from data demonstrating that the TTP protein 
cannot bind to RNA when only one of its two tandem CCCH-type zinc fingers is intact [70].  
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Similarly, it was reported that Zc3h12a requires a composition of its CCCH-type zinc finger 
and its amino-terminal adjacent so-called PIN domain to promote degradation of RNA [115].   
Currently, we cannot exclude the possibilty that Roquin is a general RNA-binding protein 
without recognizing a specific cis-element in ICOS mRNA (section 9.1.2), because we can 
also see that house keeping genes, such as Hprt1, are also bound by Roquin in 
immunoprecipitation experiments. However, ICOS mRNA was always significantly more 
enriched in these experiments (data not shown). 
Still, our data suggest that the Roquin M199R mutation, which is located within the ROQ 
domain and causes autoimmunity in san/san mice [2], might decrease the ability of Roquin to 
bind to mouse ICOS mRNA.  We can indeed confirm that the M199R mutation decreases the 
ability of Roquin to downregulate ICOS protein in T cells (Figure 8-12), as reported earlier 
[1].  However, we could not yet demonstrate that the M199R mutant has a decreased ability to 
bind to ICOS mRNA, which would be a very attractive way to explain the autoimmune 
phenotype of san/san mice. 
 
9.1.2 Roquin represses ICOS through its 3'UTR 
Trans-acting factors recognize sequence motifs or secondary structures in the mRNAs they 
regulate (section 5.3.1).  Our data together with previously published results show that 
Roquin's function is dependent on the 3'UTR of ICOS and is independent of the remainder of 
the mRNA (section 8.2.1).  First, we confirmed that Roquin represses ICOS through the 
3'UTR and that Roquin overexpression promotes ICOS mRNA decay (Figure 8-6), as 
proposed earlier [1].  Second, we demonstrated that Roquin overexpression led to 
downregulation of the reporter genes GFP, human CD4 and renilla luciferase in the context of 
the ICOS 3'UTR (Figure 8-7 and Figure 8-8).  The fact that the repression of Roquin was 
weaker for constructs that contained the GFP or human CD4 coding region than for the 
construct that contained the ICOS coding region, could indicate that regions within the coding 
region of ICOS are actually supportive for the repression of ICOS.  However, we believe that 
the differences are most likely due to differences in translation rates or protein stability.  In 
addition, we can report that Roquin does not repress ICOS via inhibition of 5'CAP-dependent 
translation (Figure 8-9).  This could indicate that mRNA decay is the major mechanism of 
repression or that translation is inhibited in a different way.  Although decapping activators 
can promote mRNA decay, deadenylation is the first step in the decay of many mRNAs 
(section 5.3.1).  Experiments confirming that Roquin downregulates ICOS by promoting 
Discussion   90 
deadenylation of the mRNA are still missing.  Therefore, Roquin could still promote ICOS 
translational repression and mRNA decay in a different way.  For instance, we did not 
experimentally exclude the possibility that Roquin is an RNase that bears intrinsic RNA 
degrading activity.  However, this seems unlikely, since Roquin actually requires additional 
factors for the repression of ICOS (section 8.2.4).   
It has not been addressed in the scope of this thesis which cis-element in the 3'UTR of ICOS 
mRNA Roquin recognizes.  It was proposed that Roquin directly or indirectly recognizes a 
miRNA-101 binding site within the 3'UTR of ICOS [1].  Therefore, we tested Roquin activity 
in Dicer- and Ago1-4-deficient cells by co-expressing Roquin with full-length ICOS.  The 
results from these experiments rule out a necessity for miRNAs in Roquin-mediated 
translational repression of ICOS (section 8.2.6 and 8.2.7).  Vinuesa and colleagues proposed 
an involvement of miRNAs based on experiments in which they already had a strong decline 
in the efficiency of Roquin-mediated repression for a reporter gene in the context of a 
minimal response element [1].  Actually, we can confirm that deletion of a region that 
contained the minimal response element caused a substantial, yet incomplete, impairment of 
Roquin-mediated ICOS downregulation (Figure 8-31).  This minimal response element, 
identified by Vinuesa and colleagues, does not contain any known cis-elements.  For example, 
three AUUUA pentamers, which could be classified as AREs (section 5.3.1), are located at 
other positions within the 3'UTR of ICOS.  It is not clear whether these can act as additional 
cis-elements for Roquin-mediated ICOS silencing or whether Roquin even recognizes a novel 
cis-element within the ICOS 3'UTR.  We assume that ICOS repression is not controlled by 
one single cis-element, but rather by a combination of cis-elements within the 3'UTR, which 
could be recognized by Roquin and so-far unknown Roquin interaction partners.  This 
hypothesis receives is supported by the deletion-mutagenesis of the ICOS 3'UTR which, in 
our hands, indicated to a contribution of different regions of the 3'UTR of ICOS to Roquin-
mediated repression (Figure 8-31).  Most likely, ICOS mRNA is regulated in a complex way 
and is incorporated into messenger ribonucleoproteins, which are committed to translational 
repression or RNA degradation.  Therefore, it cannot be excluded that a shared component of 
miRISC- and Roquin-mediated posttranscriptional gene silencing could yield in a positive 
cooperation, but only in the context of the minimal response element.  We believe that 
Roquin-mediated ICOS repression cannot be analyzed as previously described by Vinuesa 
and colleagues using a reporter gene fused to a minimal response element.  The question, 
which cis-element is recognized by Roquin, should be addressed systematically through 
point-mutagenesis in the context of full-length ICOS mRNA. 
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9.1.3 Roquin requires the P body components Rck and Lsm1 for translational 
repression of ICOS 
Many proteins involved in mRNA decay are functionally linked by the use of common factors 
and physically linked by co-localization to cytoplasmic foci, so-called P bodies (section 
5.3.2).  We found that this is also true for Roquin by demonstrating that Roquin functionally 
requires the helicase Rck and decapping activator Lsm1 (Figure 8-21) and localizes to P 
bodies (section 8.2.3).  This section will discuss the experiments which were accomplished in 
that context. 
First, we tested and confirmed the proposed localization of Roquin to stress granules [2] 
(Figure 8-16).  Similarly to Roquin, other trans-acting factors can also localize to stress 
granules [76].  Stress granules form by the aggregation of TIA-1 proteins that leads to 
translational inhibition of a distinct set of mRNAs (section 5.3.2).  In this respect it should be 
noted, that the functional requirement for a TIA-1-mediated stress response for many trans-
acting factors that localize to stress granules has not been analyzed in prior publications.  
However, MEF cells deficient for TIA-1 have been shown to be impaired in stress granule 
assembly [123].  Therefore, we tested Roquin-mediated ICOS repression in TIA-1 knockout 
MEF cells in section 8.2.3 and excluded a functional requirement of TIA-1-mediated stress 
response for Roquin activity.  The findings indicated that a cellular stress response may not be 
required for Roquin-mediated ICOS-regulation.  Therefore, we analyzed Roquin localization 
in the absence of cellular stress and found that Roquin co-localizes with Rck and Ago2 
(Figure 8-14), two proteins described to localize to P bodies (section 5.3.2).  Studies of 
deletion-mutants of Roquin identified the carboxy-terminal regions to be essential for the 
Roquin-specific localization pattern (Figure 8-18) and to be essential for Roquin-mediated 
ICOS repression (Figure 8-19).  This indicates that the P body localization is crucial for 
Roquin activity.  P bodies are cytoplasmic regions, which are enriched in translationally 
inactive mRNAs and proteins that are essential for translational repression (section 8.2.3).  
The carboxy-terminus of Roquin might facilitate the formation of aggregates of Roquin 
together with proteins that localize to P bodies.  Glutamine stretches can act as polar zippers 
in prion proteins [130].  An increased content of glutamine and asparagine (Q/N) residues is 
present in 20 different P body components, as detected in frames of 80 amino acids [131].  It 
is possible that these Q/N-rich regions, which typically occur adjacent to proline-rich regions, 
will influence protein/protein interactions between proteins that consist of Q/N-rich regions.  
Intriguingly, the carboxy-terminus of Roquin contains frames of 80 amino acids that are 
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moderately enriched in Q/N residues.  These frames are located adjacent to the proline-rich 
region and reach a maximum content of 17 Q/N residues in mouse Roquin, with 7.68 as the 
predicted average.  This observation raised the question, whether Roquin is functionally 
dependent on P body components.  Therefore, a knockdown directed against the two P body 
components Lsm1 and Rck was established (Figure 8-20).  Roquin-mediated ICOS repression 
was impaired in cells with reduced levels of Rck and Lsm1 (Figure 8-21).  Knockdown of 
Rck caused a complete block of Roquin-dependent ICOS repression.  However, knockdown 
of Lsm1, inhibited only partially Roquin activity.  As we do not have access to an antibody 
that recognizes Lsm1, we cannot exclude that the different functional impact of Lsm1 and 
Rck knockdown can reflect a weaker knockdown of the Lsm1 compared to the Rck protein.  
On the other hand, these findings could also indicate that Lsm1 has only a partial contribution 
in Roquin-mediated ICOS repression.  The Lsm1-7 protein complex is involved in mRNA 
decay by decapping, in which it recognizes oligo-adenylated mRNAs that appear after de-
adenylation of poly-adenylated mRNAs [63, 106].  Rck has also a critical role in mRNA 
decay, but it is also required for mRNA protein complex remodeling for entry into translation 
repression, storage or decay (section 5.3.1).  The strong impairment of Roquin-dependent 
ICOS downregulation in the knockdown of Rck may therefore indicate that Roquin, in 
addition to promoting ICOS mRNA decay, also causes translational repression.  Rck and 
Lsm1 knockdowns has been shown previously to inhibit P body formation [106].  Whether 
the knockdown of Lsm1 and Rck in these experiments also caused inhibition of P body 
formation or changed Roquin localization, has not been tested here.  Therefore, it is not clear 
yet if Roquin-dependent repression requires intact P bodies or just requires components that 
also localize to P bodies.  Additionally, it would be interesting to test whether overexpression 
of Roquin itself leads to the formation of P bodies.   
 
9.1.4 Roquin acts parallel to the miRNA pathway 
Although it was suggested that miRNAs are involved in Roquin-mediated ICOS repression 
[1], we did not find evidence for an involvement of the miRISC (section 8.2.6 and 8.2.7).  In 
contrast, experimental induction of miRISC formation was a strong inhibitor for Roquin-
mediated ICOS repression (section 8.2.8).  Ago2 overexpression has been demonstrated to 
promote miRNA processing [132] and to cause increased functioning of cellular RNAi 
pathways [133].  Intriguingly, overexpression of Ago2 had a negative effect on Roquin 
function (Figure 8-27).  This effect was not observed in Dicer-deficient cells that are impaired 
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in miRNA biogenesis and therefore miRISC formation (Figure 8-32).  The observed 
inhibition of Ago2 overexpression on Roquin activity could be due to the following three 
reasons: First, Roquin and Ago2 compete for the substrate, the ICOS mRNA, but Ago2 can 
only bind to the target mRNA, when miRNAs are bound [104].  Actually, Vinuesa and 
colleagues demonstrated that overexpressed miRNAs can trigger decay of endogenous ICOS 
mRNA [1].  Therefore, it remains possible that ICOS levels are not only controlled by Roquin 
but also by the miRNA pathway.  However, the pathways do not cooperate as we demonstrate 
in section 8.2.6 and 8.2.7.  Second, Roquin and Ago2 could compete for functional interaction 
with common downstream factors, such as the P body factor Rck, which is required for 
Roquin- (Figure 8-21) as well as miRNA-dependent translational inhibition [106].  Third, 
Roquin and Ago2 could compete for the direct interaction partner of Ago2, which is GW182.  
This scenario receives support from the observation that Roquin activity was also impaired 
through introduction of a dominant-negative version of GW182 (Figure 8-33), and from the 
fact that Ago2 can only bind to GW182 in the context of bound miRNAs [104], which could 
also explain why Ago2 overexpression has no effect on Roquin activity in Dicer-deficient 
cells.  In this case, the binding site of Roquin on the protein surface of GW182 should be in 
close proximity to the binding site for Ago2, since the dominant-negative version of GW182 
contains only the amino-terminal region of GW182 that binds Argonaute proteins.  An 
interaction of Roquin with this region of GW182 has not been confirmed yet due to technical 
difficulties of GW182 detection in immunoblots.  Unexpectedly, an interaction of Roquin 
with Ago2 was revealed in our immunoprecipitation experiments (Figure 8-34).  Although the 
reason for the interaction between Roquin and Ago2 remains unclear, the interaction of both 
proteins indicates that they are functionally connected, a link that may rather involve negative 
regulation, as presented in this thesis (section 8.2.9).  It is tempting to speculate that the 
negative regulation could also be mutual.  For example, Ago2 could represent a target of 
Roquin-mediated ubiquitination.  The negative regulation of miRISC formation on Roquin-
mediated ICOS repression has so far only been observed in an experimentally-induced 
situation.  It appears likely that miRISC activity is subject to physiologic regulation which so 
far has not been described.  Nevertheless, our findings provide a first example of regulated 
Roquin activity.   
 
 
Discussion   94 
9.2 Placing this work into context 
 
9.2.1 Differences to previous publications 
Previously, it has been suggested that miRNAs are involved in the repression of ARE-
containing mRNAs through the trans-acting factor TTP, as well as in the molecular 
mechanism by which Roquin silences ICOS [112].  However, it has not been clarified in these 
reports how and at which stage TTP or Roquin cooperate with the miRNA pathway.  It is 
possible that many translational repression pathways overlap [111], but often they have just 
been poorly separated from another in publications.  We report a genetic "dissection" of 
Roquin function from the miRNA pathway and demonstrate that Roquin, instead of using 
miRNAs to select its target mRNA, binds itself to RNA and is a novel trans-acting factor.  We 
can even report a negative influence of miRISC formation on Roquin activity (section 8.2.8).  
We are convinced that the previously described dependence of Roquin on miRNAs for the 
recognition of the ICOS mRNA arose from the use of a minimal response element.  This short 
47bp element was expressed in the context of a reporter and, as we suspect, exhibited aberrant 
regulation.  Therefore, we aimed to re-investigate the cis-elements for Roquin-mediated 
repression combining initial deletion analysis with point-mutagenesis of the full length ICOS 
3'UTR.  We did not yet extent our investigation to the proposed cooperation of TTP with the 
miRNA pathway, which should be easily accomplished now using the established 
experimental set-up.   
Another difference to a previous report [2] is our finding that Roquin represses ICOS TIA-1-
independently (Figure 8-17).  TIA-1 knockout cells have been shown to be impaired in stress 
granule formation [123] and Vinuesa and colleagues suggested a model in which Roquin 
regulated ICOS mRNA via co-localization of Roquin and ICOS RNA in stress granules 
leading to miRNA-induced export of ICOS mRNA into P bodies [1].  We cannot exclude the 
possibility that Roquin acts in an undiscovered stress pathway that is independent of TIA-1.  
However, we consider this unlikely since we show that Roquin-dependent ICOS repression 
depends on factors important for P body formation and function (section 8.2.4).  We think that 
the localization of Roquin to stress granules that we confirmed could be due to the 
relocalization of an interaction partner of Roquin that, upon stress, translocates into stress 
granules and may be necessary for the regulation of other targets.  Actually, many other trans-
acting factors, including TTP, have been shown to localize to stress granules (section 5.3.2), 
but the requirement for TIA-1 by these trans-acting factors has not been analyzed to date.  
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Nevertheless, our data do not exclude a stress-responsive regulation of ICOS through Roquin, 
which might occur during the so-called integrated stress response.  This response appears to 
be TIA-1-mediated and inhibits interleukin-4 translation but not transcription during the first 
antigen-encounter of a naïve CD4 T cell and is relieved upon restimulation of the effector T 
cells [88]. 
Taken together the differences to previous publications mostly affect the concept of the 
molecular mechanism of Roquin-mediated ICOS repression.  This concept is currently 
forming and therefore requires continuous adjustments before a full understanding has been 
obtained. 
 
9.2.2 Implications for MNAB 
Mouse MNAB and mouse Roquin are two highly homologues proteins with an amino acid 
identity of 72 % in the amino-terminal domains (Figure 6-3), indicating that these proteins 
could exert similar functions.  Only one previous report about human MNAB can be found in 
the literature, describing MNAB as membrane-associated nucleic acid binding protein [114].  
We were curious, whether MNAB, similar to Roquin, can also repress ICOS in T cells.  The 
data presented here show that ICOS levels remain largely unaffected by overexpression of 
MNAB in CD4 T cells (Figure 8-12 a).  However, we discovered that a chimera consisting of 
the carboxy-terminus of Roquin and the amino-terminus of MNAB is able to downregulate 
ICOS (Figure 8-13).  This indicates that MNAB might also function as a translational 
repressor for other mRNAs, with a range of targets that is probably not restricted to ICOS 
mRNA.  We show that the amino-terminus of Roquin can bind to ICOS mRNA, the part that 
is highly homologues to MNAB.  In support of this notion, MNAB has been reported to bind 
to DNA in vitro [114].  Therefore, we would expect that MNAB also binds to ICOS mRNA.  
It would be very interesting now to identify mRNA targets of MNAB and to confirm that 
MNAB can repress their translation.  MNAB and Roquin share only amino acid 34 % identity 
in the carboxy-terminal regions and our experiments confirm that Roquin's carboxy-terminus 
has evolved for efficient ICOS repression.  Localization studies demonstrate that the carboxy-
terminus determines Roquin localization to P bodies (Figure 8-18).  We were curious whether 
MNAB can also localize to P bodies or whether this is unique for Roquin.  MNAB was 
described to localize to cytoplasmic spots, but it was suggested that these are ER-associated 
[114].  Here, we report co-localization of MNAB and Roquin, indicating that MNAB 
localizes to P bodies, too (Figure 8-15).  However, MNAB seems to be more diffusely 
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distributed in the cytoplasm.  Whether this difference, which still has to be studied more 
intensively, can explain why Roquin is more efficient in ICOS repression, is unclear at this 
point.  Roquin could also have higher activity due to other reasons, for example by binding to 
different interacting partners.  The co-localization of MNAB and Roquin could also indicate 
that these highly homologues proteins interact with each other.  Interestingly, they show 
similar mRNA expression in several lymphoid organs (Figure 8-11 b), but with higher protein 
expression of MNAB, at least in thymi (Figure 8-11 a).  It would be interesting to test whether 
Roquin and MNAB interact and whether both proteins cooperate.   
In summary, the here presented localization of MNAB and its possible RNA-binding activity 
strongly imply that MNAB could also be a trans-acting factor, which might be more efficient 
in a similar pathway of repression in other cell types or by acting on different targets than 
ICOS mRNA. 
 
9.2.3 Importance of the results for autoimmune diseases 
In this study, experimental proof is presented that excludes the requirement or even the 
contribution of miRNAs in Roquin-mediated ICOS repression.  We have reached these 
conclusions due to experiments that analyzed Roquin-mediated repression of full-length ICOS 
mRNA and on the basis of genetic evidence.   
Roquin function is critical in follicular helper T (TFH) cells to prevent T cell help to self-
reactive B cells and to suppress the production of autoantibodies.  In fact, a single point-
mutation in Roquin has been shown to cause systemic lupus erythematosus-like disease in 
homozygous mice.  An earlier publication by Yu and colleagues [1] implicated that 
autoantibody production in lupus-like disease was under the control of miRNAs and 
suggested that Roquin has to cooperate with the miRISC in TFH cells to silence ICOS.  These 
conclusions promote the idea that miRNA-targeting of ICOS should allow for new future 
therapies [1].  Consequently, our demonstration that Roquin is a trans-acting factor that binds 
to ICOS mRNA without the contribution of miRNAs will be enlightening for ongoing applied 
research and may help to adjust strategies of therapeutic intervention in systemic lupus 
erythematosus. 
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9.3 Outlook and future directions  
 
9.3.1 Identification of the Roquin-bound cis-element 
Our data demonstrate that ICOS mRNA binding by Roquin is essential for its repression by 
Roquin.  Although we identified domains within Roquin that bind to ICOS mRNA (section 
8.2.5), we could not identify the bound element within the ICOS mRNA.  In principal, it 
should be possible to uncover the cis-element that is recognized by Roquin through a 
systematic deletion-mutagenesis of the 3'UTR of ICOS coupled with functional and RNA-
binding assays.  Because we speculate that Roquin might recognizes more than one cis-
element within the ICOS 3'UTR (section 9.1.2) and that ICOS is more likely regulated in a 
complex way, it may be more promising to first identify additional targets of Roquin in a 
whole-genome approach (section 9.3.3).  Bioinformatic comparison of target 3'UTR may then 
reveal common cis-acting elements, which can thereafter be experimentally confirmed 
(section 9.3.3). 
 
9.3.2 Role of the RING finger domain in Roquin and MNAB. 
The evolutionary conservation of the RING finger domain in MNAB and Roquin suggests 
that these proteins could regulate target protein levels via E3 ubiquitin ligase activity (section 
5.3).  To address the role of the RING finger in Roquin we deleted the whole domain or point-
mutated critical cysteines in the RING finger, and tested the importance of the RING finger 
for Roquin-mediated ICOS repression.  For both mutants a reduced activity to downregulate 
ICOS was observed, as compared to Roquin wildtype (Figure 8-10).  These results indicate 
that the RING finger helps to reach the full extent of translational inhibition of ICOS, but is 
not essential.  Other E3 ubiquitin ligases, like Cbl-b, Itch and Grail, which are also involved 
in the control of immune reactivity against self-antigens, critically depend on their intact 
RING fingers or HECT domains [26].  In this respect, Roquin appears to differ from these 
proteins that are thought to entirely depend on their E3 ligase activity ubiquitinylating 
proteins to target them for degradation [25, 120, 121].  However, it has not been resolved in 
the framework of this thesis whether the partial contribution of the RING finger of Roquin 
results from E3 ligase activity or other possible functions of the RING finger.  The fact that 
Roquin did not show autoubiquitination in vivo ubiquitination assays [134] (data not shown) 
indicates that the RING finger of Roquin might not exert E3 ubiquitin ligase activity, or 
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cannot be detected by autoubiquitination in cells.  However, it is also possible that the RING 
finger is involved in an unanticipated molecular function.  There are previous reports 
documenting molecular functions for RING domains other than E3 ubiquitin ligase activity.  
For instance, RING domains have been described to fulfill a function in the assembly of 
macromolecular structures [135, 136].  This function seems unlikely to apply to the RING 
domain of Roquin.  Although Roquin appears to be part of macromolecular structures in P 
bodies, as seen by confocal microscopy (Figure 8-14) we showed that deletion of the RING 
finger domain did not change the Roquin-specific punctate pattern (Figure 8-18).  Another 
report stated that the RING domain of PML can repress 5'CAP-dependent translation by 
direct inhibition of the translation initiation factor eIF4E [137].  This function also seems 
unlikely to hold true for the RING finger domain of Roquin, since we can show that at least 
one function of Roquin, namely Roquin-mediated ICOS repression, is independent of 5'CAP-
dependent translation (Figure 8-9).  Finally, the observed small negative effect of RING 
finger deletion on Roquin binding to ICOS mRNA could be interpreted such that the RING is 
one of the domains that contribute to a composite surface of the RING finger, ROQ domain 
and zinc finger that together bind to RNA. 
 
9.3.3 Which other mRNA targets are regulated by Roquin? 
Differential gene regulation has been determined for CD4 T cells derived from san/san and 
wildtype mice [2].  However, this and later publications [19, 23] demonstrate that expression 
of the M199R mutant of Roquin in san/san mice predominantly changed the activation status 
of CD4 T cells towards activation and furthermore shifted the percentage of helper T cell 
subsets by favoring the TFH cell phenotype.  It was just recently discovered in three  
publications that the transcription factor Bcl-6 is important for TFH cells.  It was shown that 
Bcl-6 is necessary and sufficient for in vivo differentiation of TFH cells [138], is required for 
programming TFH cell generation [139] and directs follicular T helper cell lineage 
commitment [140].  Furthermore, Bcl-6 mRNA has a relative long 3'UTR (1600 bp for 
transcript variant 2 in human).  Therefore, Bcl-6 mRNA is a promising candidate for Roquin 
regulation.  However, whether Bcl-6 mRNA or other deregulated mRNAs in san/san mice are 
direct targets of Roquin regulation will have to be verified experimentally.  Vinuesa and 
colleagues reported that neuropilin 1 mRNA was downregulated upon Roquin overexpression 
[1] and that IL-2 mRNA expression is higher in san/san CD28 -/- mice than in Roquin 
wildtype CD28-/-  mice.  This indicates that IL-2 mRNA might also be a target of Roquin.  
Discussion   99 
We can report additionally that overexpression of Roquin in T cells negatively effects IL-2 
and CD40L protein expression after restimulation (data not shown).  We did not test mRNA 
levels in these experiments and cannot exclude that these are indirect downstream effects of 
Roquin-mediated repression of ICOS or T cell differentiation.  A global approach to analyze 
mRNAs in cells with short-term ectopic over-expression of Roquin in activated follicular 
helper T cells should be performed in order to measure differential expression of direct 
mRNA targets.   
 
9.3.4 Which other proteins cooperate in Roquin mediated-translational 
repression? 
Since many trans-acting factors exert their function via interaction with the general mRNA 
decay machinery (section 0), we have to assume that Roquin, in addition to Rck and Lsm1, 
also requires other factors involved in mRNA decay for the repression of ICOS.  Another 
trans-acting factor that exerts gene-specific regulation and that has been well studied, is TTP.  
TTP requires Lsm1 for its activity, similar to Roquin.  In addition, TTP has been shown to 
interact with CCR4 (a component of the CCR4-Not deadenylation complex), with DCP2 (a 
component of the DCP1:DCP2 decapping complex) and the 5'-3' exonuclease XrnI [75].  
Therefore, it is very likely that also Roquin requires factors that can promote either 
deadenylation or decapping of mRNAs and thereby assist in ICOS repression.  It would 
therefore be of great interest to identify Roquin associated factors that participate in 
translational repression and thus also play a role in the prevention of autoimmunity. 
 
9.3.5 How is Roquin activity regulated? 
We find that induced miRISC formation interferes with Roquin-mediated ICOS repression 
(section 8.2.8).  ICOS levels have to be tightly regulated in order to prevent reactivity against 
self (section 5.2).  It is therefore interesting to study the mechanisms by which miRISC 
formation interferes with Roquin activity.  Although miRISC formation appears to be a 
constitutive process, globally decreased levels of mature miRNAs have been reported in the 
development of cancer [141].  In addition, Roquin activity could be altered by modification of 
Roquin itself.  This could be achieved for example through phosphorylation of Roquin.  In 
support of this hypothesis, Roquin has been identified in a large-scale phosphorylation 
analysis of mouse liver [142].  The analysis identified Roquin-peptides phosphorylated at the 
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amino acid positions 1107 and 1110 in the protein.  Phosphorylation of Roquin could 
therefore be one way to either activate or inactivate the protein.  Phosphorylation could alter a 
binding site for interacting proteins or lead to induced degradation or prevent destruction of 
Roquin and thereby affect ICOS levels. 
  
 
 
 
The interest in Roquin was sparked amongst immunologists and molecular biologists after it 
had been suggested that Roquin cooperates with miRNAs to regulate ICOS [1].  This 
regulation is essential for the prevention of autoimmune diseases [2].  This thesis uncovers 
that Roquin does not cooperate with the miRNA pathway to repress ICOS.  Instead, we 
propose a model in which Roquin-mediated repression is parallel to posttranscriptional gene 
silencing by miRNAs.  Our evidence includes the new findings that induced miRISC 
formation inhibits Roquin activity and that Roquin and Ago2 interact with each other.  
Furthermore, we demonstrate that Roquin binds ICOS mRNA, localizes to P bodies and 
requires P body factors for its function.  These characteristics are in common with miRNAs 
during posttranscriptional gene silencing. 
We discover that the newly defined ROQ domain of Roquin is a novel RNA-binding domain, 
by showing that it is essential for ICOS mRNA binding. 
The Roquin protein was only recently discovered and research concerning its molecular 
mechanism is still in its infancy.  Revealing the mechanism by which Roquin represses ICOS 
makes a contribution to our understanding of posttranscriptional gene regulation and may 
enable future identification of target structures for therapeutic intervention in autoimmune 
diseases.   
 
10 Conclusion
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